

VIENNA LIFE SCIENCE REPORT 2024/25



Strengthening the life sciences is a cornerstone of Austria's science and industry policy. As a dynamic economic driver, the sector excels in research, groundbreaking innovation, strong value creation, and high-quality job opportunities.

Vienna, home to more than half of Austria's life sciences community, has played a leading role for decades. This report provides valuable insights into the entire value chain, benefiting healthcare and other sectors that impact society at large.

The latest figures confirm that the BMWET's long-term commitment to supporting the life sciences is delivering results. Beyond general funding programs, targeted initiatives have created clear competitive advantages.

Austria remains dedicated to fostering its thriving life sciences ecosystem. The FFG Life Science Programme has been equipped with €95 million from 2022 to 2026 to foster R&D across all technology readiness levels. Meanwhile, aws LISA – Life Science Austria, managed by Austria Wirtschaftsservice, continues to offer tailored support for founders and start-ups at every stage of development, strengthens Austria's regional life sciences clusters such as LISAVienna, and positions the country as a premier international business hub.

From 2024 to 2026, the aws Preseed and Seedfinancing Deep Tech program will allocate €19 million to start-ups, further cementing Austria's status as a center for cutting-edge innovation in the heart of Europe – where life sciences play an integral role.

Innovation drives economic success and job creation – which is why Vienna has spent more than 20 years investing in innovation, particularly in the area of life sciences, establishing attractive conditions and premises. Today, Vienna ranks among Europe's leading life sciences hubs and is Austria's top location in this field.

The life sciences directly contribute to human flourishing, both through medical advances and by making sustainable our relationship with nature. Thus, the sector contributes not just to our city's economy but to the quality of life that helps attract top talent. Over 40% of local companies focus on R&D or manufacturing, which means that Viennese will continue to have access to cutting-edge medical technology and healthcare, as well as to high quality jobs.

The launch of AI biomedical research institute AITHYRA shows Vienna's international appeal, while the new Eric Kandel Institute for Precision Medicine signals bold ambitions.

Growth is strong: from 2020 to 2023, employment rose by 8% and revenues by 22%. Global players like Boehringer Ingelheim, Octapharma, and Takeda are investing here – indeed, the Vienna region is home to each of the 20 largest global pharma, biotech and medical device companies, which are bolstered by strong academic institutions and innovative startups.

We all benefit from this thriving ecosystem, and we will continue to invest in its growth. Together, we're creating solutions for the challenges ahead – let's keep going!

© BKA/Andy Wenzel



Wolfgang
Hattmannsdorfer
Federal Minister of
Economy, Energy and
Tourism

© PID David Bohmann



Michael
Ludwig
Mayor and
Governor
City of Vienna

Austria's life sciences sector holds a strong reputation within the European ecosystem, gaining recognition for its contributions to science and technology.

For over 20 years, Austria Wirtschaftsservice (aws), the Austrian national promotional bank, has played a key role in strengthening the life sciences sector through the LISA – Life Science Austria program. This initiative showcases Austria's strengths on the international stage, uniting all regional clusters under one umbrella. Programs like aws BoB – Best of Biotech help researchers and students turn ideas into start-ups, while academic spin-offs benefit from incubators funded by aws AplusB Scale-up.

The aws Spin-off Initiative is further supporting these efforts. To advance deep-tech companies and innovative solutions, aws Preseed and Seedfinancing offer critical funding, complemented by additional services for IP protection and networking. Growth and internationalization are facilitated through the aws Venture Capital Initiative, founder and SME funds, as well as dedicated guarantees and loans. Recognizing Vienna's strategic role in the life sciences – from academia to business – aws has long collaborated with the Vienna Business Agency to strengthen this sector.

LISAvienna, our joint cluster platform, ensures innovative start-ups receive expert guidance, combining regional and national perspectives. Explore this report to discover more about Vienna's top life sciences community!

The last few months of 2024 were pivotal for life sciences in Vienna, which won the bid to house AI-based biomedical institute Aithyra and saw the expansion of pharmaceutical heavy-hitters Boehringer Ingelheim and Takeda. Indeed, life sciences were among the top five industries that moved to or established offices in Vienna last year – demonstrating the city's strong international appeal.

Today's success is the result of excellent partnerships and a forward-thinking strategy that dates back to the 1990s. The city has consistently invested in growth, making life sciences a key innovation driver – from digitalization and smart manufacturing to groundbreaking therapies. Vienna a future-ready hub for research and business, as well as a leading healthcare city.

Vienna Business Agency continues to play a central role in this success by offering a comprehensive portfolio of tailored consulting, targeted funding, and state-of-the-art infrastructure, including the Startup Labs, the Vienna BioCenter Core Facilities and the coming Life Science Center Vienna with cutting-edge laboratory and office spaces.

Our cluster platform LISAvienna – a long-standing collaboration between the Vienna Business Agency and Austria Wirtschaftsservice – has supported the community with expert guidance and strategic networking for more than 20 years. Together, we've accomplished a great deal, and we're just getting started – full speed ahead!



© aws | Prader

Gerfried Brunner
Managing Director
Austria
Wirtschaftsservice

© Wirtschaftsagentur Wien
Paul Bauer

Dominic Weiss
Managing Director
Vienna Business
Agency

Dear Readers,

Vienna's life sciences sector is flourishing – and LISAvienna is proud to be part of its continued success story, actively supporting the sector's development for nearly 25 years. We are committed to helping all stakeholders turn science into solutions: from early-stage startups to global corporations, from basic research to industrial manufacturing.

Life sciences are essential for ensuring high-quality healthcare for a growing and ageing population and the challenges posed by climate change. The sector has not only grown but become more diverse. Personalised medicine and digital health, bioeconomy and additive manufacturing technologies are shaping the innovations of tomorrow. Dynamic young start-ups, in particular, are contributing groundbreaking ideas and technologies to secure the long-term functioning of our healthcare systems. Locally developed drugs, diagnostics, medical devices and digital health solutions are reaching the market, and the underlying technologies are also impacting related industries, such as food, chemicals, textiles, and veterinary care. The pipelines are full of exciting innovations – including organoids, CRISPR and other cutting-edge technologies – that are transforming both research and business. Vienna plays a central, key role in this development: it is home to more than half of Austria's life sciences sector. Vienna is truly an innovation hub.

The data, facts, and trends in this sixth and latest Vienna Life Science Report speak for themselves: life sciences companies in Vienna are thriving, and the city has become a true life sciences hotspot with the talent, infrastructure, and collaborative spirit to prove it.

On behalf of the entire LISAvienna team, we extend our warmest thanks to all the companies, research institutions, and organisations that comprise Vienna's life sciences community: Thank you for contributing data to this report and, most importantly, for your dedication to innovation and addressing real-world challenges.

We look forward to continuing this journey together.



Philipp Hainzl

Managing Director, LISAvienna

Executive Summary

Life sciences are one of Vienna's most dynamic innovation engines, strengthening the city's position as a leading hub in this sector in Europe. Applying the latest standards in innovation research, the Vienna Life Science Report 2024/25 confirms sustained growth in both scientific excellence and economic impact.

Vienna is home to 754 life sciences organisations, including 646 companies and 19 renowned research and education institutions, with a total workforce exceeding 49,000 employees. Although the city accounts for just 21% of Austria's population, it represents over half of the nation's entire life sciences sector. Annual revenues reached €22.7 billion in 2023 and between 2020 and 2023, employment grew by 8%, and 83 new life sciences companies were established.

A closer look at the segments shows that the regional biotechnology and pharmaceutical business sector includes 349 companies with 22,988 employees and a total turnover of €18.4 billion. Additional 297 companies are included in the medical device business sector with 10,667 employees, adding €4.4 billion in revenue.

Vienna's innovation pipeline is driven by strong academic performance: in 2023 alone, Vienna's research and education institutions produced 8,800 publications. More than 34,000 students were enrolled in life sciences programmes, reflecting deep and growing interest in the field and helping to ensure a future-ready talent pool.

These developments confirm the long-term success of Vienna's strategy of cultivating a robust life sciences ecosystem over the past 25 years. By fostering innovative solutions in medicine and environmental technologies, the sector contributes significantly to both human health and planetary well-being – enhancing the quality of life that Vienna is globally recognised for and strengthening its appeal to international talent.

All the top 20 global biotechnology, pharmaceutical, and medical device companies (by 2023 sales) maintain a strategic presence in the Vienna region, and the dynamic start-up and scale-up scene here is pushing the frontiers of innovation exemplified by activities ranging from drug discovery to AI-driven digital solutions for a modern and effective healthcare system. Publicly announced equity investments and financing milestones, including licensing deals and M&A, have consistently reached the triple-digit million-euro range annually.

More detailed insights, data and facts are presented in this report.




Content

Vienna – Life sciences hub in the heart of Europe

Statistics	10
Life sciences in Vienna	12
Key figures at a glance	13
Vienna: At the core of Austria's life sciences industry	17
The biotechnology and pharmaceutical business sector in Vienna	19
The medical device business sector in Vienna	28
Facts and figures on research and education in Vienna	33
Other organisations shaping Vienna's life sciences cluster	36
Innovation hub Vienna	39
LISAvienna: the cluster platform at the heart of Vienna's life sciences ecosystem	39
Life sciences in Vienna: drivers, structures, dynamics	40
On the power of drug development, new platform technologies and innovative services in Vienna	43
Digital health and AI transforming healthcare	47
In-vitro diagnostics and medical devices made in Vienna	49
Growing bioeconomy network at the heart of Europe	52
Global market leaders value their operations in Vienna	53
Hotspots throughout the City of Vienna – where proximity facilitates innovation	56
Hospitals and university clinics: the core of clinical research	58
Methods	63
Survey and definitions	64
Additional references	66
Annex	68
New life science companies in Vienna	69
Biotechnology / pharmaceutical companies in Vienna covered by the statistical analysis	74
Medical device companies in Vienna covered by the statistical analysis	88
Research and education organisations in Vienna covered by the statistical analysis	100
Other organisations in Vienna covered by the statistical analysis	101
Equity investments and other major capital infusions	105
Licensing, M&A activities, site expansions and additional agreements	109
Focus of innovative medical device companies in Vienna	115
Focus of innovative biotechnology / pharmaceutical companies in Vienna	121
Drug discovery and development in Vienna	131

Vienna – Life science hub in the heart of Europe




Life Sciences in Vienna

In 2023, Vienna's life sciences sector comprised 646 companies, 19 research institutions, and 89 other organisations – amounting to 754 entities active in the field with a total workforce of 49,056. Biotechnology and pharmaceutical companies employed 22,988 people, while medical device companies employed a further 10,667. In addition, 12,634 individuals were employed in academic life sciences activities at universities and non-university research institutions. A further 2,767 people were employed in life sciences roles within non-commercial, non-academic organisations. Vienna's life sciences companies generated €22.7 billion in revenues in 2023.

- Biotech/pharma companies: 22,988
- ⊕ Medical device companies: 10,667
- ▨ Academia: 12,634
- Other organisations: 2,767

- Biotech/pharma companies: 349
- ⊕ Medical device companies: 297
- ▨ Academia: 19
- Other organisations: 89



- Biotech/pharma companies: €18.4 bn
- ⊕ Medical device companies: €4.4 bn

34,145 students were enrolled in life sciences programmes at Vienna's universities, including private universities and universities of applied sciences. Academic institutions collectively published 8,800 scientific articles in 2023.

Figure 1: Key figures for Vienna's life science sector (data: 2023)

Key figures at a glance

Vienna is home to a thriving life sciences sector, marked by continuous growth across key indicators. The total number of organisations, employees, students, scientific publications, and overall revenues has steadily increased. Figure 2 highlights an impressive upward trend: Compared to 2020, 2023 saw a 4% rise in the number of organisations, an 8% increase in employees, 3% more publications, 6% more students, and a 22% growth in total revenues.

Biotechnology and pharmaceutical business sector

In 2023, Vienna was home to 349 biotechnology and pharmaceutical companies with a turnover of €18.4 billion and 22,988 employees. 55 of these companies were newly founded in 2021–2023. In 2023, there were 8% more employees in this sector than in 2020 and revenues increased by 30%. All indicators point to a growing biotechnology and pharmaceutical business sector. The sector is also relatively young, with 42% of all companies founded in 2013 or after. Half of the companies (174) are involved in the research, development, and manufacturing sectors, while the other half (175) focus on supply, services, and sales.

Medical device business sector

In 2023, Vienna's medical device business sector included 297 companies, of which 89 (30%) were active in research, development, manufacturing, while 208 (70%) operated in supply, services, sales. These companies employed a total of 10,667 people and generated a turnover of €4.4 billion. In 2023, it is estimated that there were 14% more employees in this category than in 2020 and revenues decreased by 3%. The decrease in revenues is probably a consequence of the COVID19 pandemic in 2020. 28 new medical device companies were founded in 2021–2023. In 2023, 36% of all companies were ten years old or less.

Life sciences in Vienna, 2020-2023




Figure 2: Key figures for Vienna's life sciences sector in 2020 and 2023

Academia

Vienna is home to six universities, two universities of applied sciences and eleven non-university research institutions. Together they employ 12,634 individuals in life sciences. In 2023, researchers affiliated with institutions in Vienna contributed to 8,800 peer-reviewed scientific publications, including co-authored papers with collaborators from outside the city. From 2020 to 2023, the number of students in life sciences rose from 32,125 to 34,145, reflecting a 6% growth, according to uni:data, the database of the Austrian Federal Ministry of Education. At universities of applied sciences, the number of life sciences students rose by an impressive 32%, while public and private universities together reported an increase of nearly 4%.

Traditional universities and applied sciences institutions alike are fuelling spin-off creation. 36 of all life sciences companies in Vienna were identified as university spin-offs – 23

in the biotechnology and pharmaceutical sector, and 13 in the medical device sector. 20 biotechnology and 7 medical device spin-offs operate in research, development or manufacturing, highlighting the strong innovation and research orientation of companies with close ties to academia.

Advancing with artificial intelligence

Survey data show that companies and research institutions in Vienna are making significant strides in the implementation and application of artificial intelligence. Figure 3 presents a comparison of the business sectors (biotechnology and pharmaceutical plus medical devices) and research and education institutions. Nearly 60% of respondents report that they are already using AI, are in the progress of implementing it, or are in the planning and testing stages. While the sample size for research and education institutions is smaller, their responses indicate highly advanced levels of AI integration.

Implementation of artificial intelligence in the Viennese life sciences sector, 2023




Figure 3: State of AI usage by organisation type, 2023, numbers of observations: business sectors: 101, research and education institutes: 8

Other organisations

This category includes various non-commercial and non-academic organisations engaged in life sciences activities. 89 such organisations were considered in the analysis: 13 governmental entities, 50 special-interest groups, 7 funding and support agencies, 4 start-up service-providers and 15 additional organisations working in life science research to some extent. They employed an estimated 2,767 people. The number of employees rose by 14%, from 2020 to 2023.

The ongoing expansion and success of life sciences in both the business and academia would not be possible without the substantial support of such governmental and non-governmental bodies.

Methodical changes

The current data are not directly comparable with those from the previous report due to improvements in methodology as well as new inclusions and recategorisations of existing companies. As a result, estimates for 2020 have been recalculated using the updated method and dataset. Additional details are outlined in the Methods chapter.





EUR 300.000,-
aws Preseed
Financing the pre-seed phase

EUR 1.000.000,-
aws Seedfinancing
Financing the start-up phase
of life science companies

We bring
Life Sciences
to Life

With aws Preseed | Seedfinancing - Deep Tech, we support and finance projects from the idea to the market launch with grants up to 300 TEUR or up to 1 MEUR. This enables us to close financing gaps for deep tech start-ups that arise during the transition from research to commercial utilisation. The aim is the sustainable foundation of competitive, economically independent, innovative, technology-orientated companies. Consultancy services of aws on founding, growth and innovation protection make an important contribution to this.



Vienna: At the core of Austria's life sciences industry

Vienna is not only Austria's capital; it has been establishing itself as the country's life sciences hub for decades. Vienna is home to about 21% of Austria's population, accounts for 25% of the country's GDP and for 31% of national R&D expenditures, yet it hosts about half of Austria's life sciences activities.

More specifically, Vienna hosts 55% of the country's life sciences companies, which collectively account for 46% of employees, 57% of turnover and 50% of R&D expenditures, as shown in Figure 4. Vienna's strong standing is also reflected in other indicators. For example, WPZ Research's database of Austrian startups and spin-offs identifies 71 university spin-offs active in life sciences, with 36 (51%) based in Vienna. This prominent position is further confirmed by official statistics. For example, 57% of corporate R&D in the industry sector "manufacture of medical and dental instruments and supplies" (ÖNACE code C32.5) takes place in Vienna (*Statistics Austria*).

Total shares of Vienna's life science business sectors, 2023




Figure 4: Vienna's shares in Austria's life sciences business sectors in terms of number of companies, employees, total turnover and the R&D expenditures of dedicated life sciences companies, 2023

In 2023, 646 companies employed 33,655 people in life sciences and generated revenues totalling €22.7 billion. While just over half (54%) of the companies in Vienna belong to the biotechnology and pharmaceutical business sector, their share of total employment and revenue is significantly higher, at 68% and 81%, respectively.

In particular, the research, development, manufacturing segment within the biotechnology and pharmaceutical business sector is quite large, partly attributable to units of several multinational companies located in Vienna. In contrast, large research, development, manufacturing companies within the medical device business sector in Austria are predominantly located outside of Vienna.

Research, development, manufacturing

41% of all life sciences companies in Vienna are active in research, development and/or manufacturing. These 263 enterprises employed 16,890 people in 2023, generating a total turnover of €9.1 billion. Of these, the biotechnology and pharmaceutical business sector accounted for 14,692 employees in Vienna and a turnover of €8.5 billion.

The medical device business sector had 2,198 employees and revenues of €550 million. It is therefore not surprising that 18 of the 20 largest research, development, manufacturing companies (measured by number of employees) belong to the biotechnology and pharmaceutical business sector.

	Companies		Employees		Revenues in € m	
	2020	2023	2020	2023	2020	2023
Life science companies in total	616	646	30,603	33,655	18,621	22,714
Biotechnology and pharmaceutical companies	326	349	21,221	22,988	14,109	18,358
Medical device companies	290	297	9,381	10,667	4,512	4,356
Research, development, manufacturing	223	263	13,986	16,890	6,978	9,093
Biotechnology and pharmaceutical companies	149	174	12,226	14,692	6,275	8,543
Medical device companies	74	89	1,761	2,198	703	550
Supply, services, sales	393	383	16,616	16,766	11,643	13,621
Biotechnology and pharmaceutical companies	177	175	8,996	8,296	7,834	9,814
Medical device companies	216	208	7,621	8,469	3,809	3,807

Table 1: Key figures for life sciences companies in Vienna in 2020 and 2023

Moreover, Vienna is a highly attractive location for multinational companies. Of the 20 largest research, development, manufacturing companies, measured by number of employees, 17 are subsidiaries of foreign companies. Vienna continues to demonstrate its appeal as an attractive business location with impressive 20% growth in employee numbers from 2020 to 2023.

A total of 27 university spin-offs, 20 in the biotechnology and pharmaceutical sector and 7 in the medical device sector, highlight Vienna's top environment as a hub for young companies advancing research and the development of innovative products, processes, and services in the life sciences.

Overall, companies with research, development or manufacturing activities tend to be relatively young, 41% were five years old or less as of 2023. In the biotechnology and pharmaceutical business sector 38% were five years old or less in 2023, compared to 47% in the medical device business sector. Dedicated biotechnology companies are among the youngest, with 52% five years old or less in 2023, highlighting this dynamic and disruptive industry. In stark contrast, 71% of

pharmaceutical companies were 20 years old or more in 2023, indicating a stable and mature industry.

Supply, services, sales

Supply, services, sales companies employed 16,766 people in 2023, generating a total turnover of €13.6 billion. Unlike research, development, manufacturing companies, their employment figures are more evenly distributed: the biotechnology and pharmaceutical business sector employed 8,296 people in Vienna, while the medical device business sector employed 8,469. However, turnover differs significantly, with €9.8 billion generated by biotechnology and pharmaceutical companies, compared to €3.8 billion generated by medical devices companies.

Overall, the supply, services and sales sector is less research-intensive than the research, development, manufacturing sector. Nevertheless, some companies are highly innovative. Among these, nine are university spin-offs, including six in the medical device sector.

The biotechnology and pharmaceutical business sector in Vienna

In 2023, a total of 349 biotechnology and pharmaceutical companies were active in Vienna, employing 22,988 people and generating revenues of €18.4 billion. Of these 349 companies, no fewer than 55 were founded in 2021–2023. The majority of these new companies – 41 in total – are engaged in research, development, manufacturing, while the remaining 14 operate in supply, services, sales.

Vienna’s shares within Austria’s biotechnology and pharmaceutical business sector are illustrated in Figure 5. Two-thirds (66%) of the companies are located in Vienna, employing 54% of the sector’s workforce and generating 63% of its total turnover. While this sector is expanding nationwide, Vienna’s figures are particularly noteworthy: with 55 newly founded companies and 32 closures, the net increase amounts to 23 companies; the total number of employees rose by 8%, and revenue increased by 30%.

Shares of Vienna’s biotechnology and pharmaceutical business sector, 2023




Figure 5: Total share of Vienna in Austria’s biotechnology and pharmaceutical business sector by number of companies, employees and turnover, 2023

A surge in new companies

Table 2 provides detailed insights into the six company categories within the biotechnology and pharmaceutical business sector, as well as their classification into the overarching meta-categories research, development, manufacturing and supply, services, sales. By including companies identified in the current report that were founded in 2020 or before, the number in 2020 increases to 326. Notably, most newly established companies are in the dedicated biotechnology category, with 36 new companies and 12 closures, resulting in a net gain of 24 companies compared to 2020. This net gain surpasses that of the sector as a whole. In contrast, the number of other biotechnology active companies and pharmaceutical companies remained largely unchanged from 2020 to 2023. A full list of companies included in the 2023 sample is provided in the annex (Table 11).

The number of companies and employees within the supply, services, sales category declined slightly under the revised method and revenues increased. In 2021–2023, 14 new companies were founded and 16 ceased operations. 56 companies founded in 2020 or earlier but previously unrecorded are now included in the dataset for 2020 and 2023.

	Companies		Employees		Revenues in € m	
	2020	2023	2020	2023	2020	2023
Biotechnology and pharmaceutical companies in total	326	349	21,221	22,988	14,109	18,358
Research, development, manufacturing	149	174	12,226	14,692	6,275	8,543
Dedicated biotechnology companies	95	119	1,243	1,779	461	879
Other biotechnology active companies	37	37	10,177	12,008	5,358	7,173
Pharmaceutical companies	17	18	805	905	456	491
Supply, services, sales	177	175	8,996	8,296	7,834	9,814
Core suppliers	30	31	935	903	435	1,119
Core service providers	34	30	4,865	4,128	1,855	1,942
Core sales and distribution companies	113	114	3,195	3,265	5,543	6,754

Table 2: Key figures for the biotechnology and pharmaceutical business sector in Vienna for 2020 and 2023

Almost 14,700 employees in research, development, manufacturing ...

As shown in Table 2, the majority (14,692) of the 22,988 employees work in research, development, manufacturing companies. Of these, 12,008 are employed by other biotechnology active companies, which, by definition, also operate in fields outside of life sciences. According to the survey, approximately 38% of their employees (5,255) are directly involved in biotechnology-related activities. Dedicated biotechnology companies employ 1,779 persons, while more traditional pharmaceutical companies account for 905 employees.

Table 2 also shows that 8,296 are employed in supply, services, sales companies. Of these, core suppliers employ 903, core service providers 4,128, and core sales and distribution companies 3,265. The term “core” is used for companies that specifically develop or design goods and services for use in the development, production or distribution of biotechnology and pharmaceutical products. “Other” companies in supply, services, sales are not included in the respective categories but can be found

in the Austrian Life Sciences Directory (www.lifesciencesdirectory.at).

...generating revenues of over €8.5 billion in 2023

Research, development, manufacturing companies generated €8.5 billion in revenues in 2023, representing 47% of the biotechnology and pharmaceutical business sector’s total revenue of €18.4 billion. Most of this turnover derives from other biotechnology active companies, which generated €7.2 billion despite the fact that only 37 companies fall into this category. The high collective turnover is driven by the presence of some giants: three companies each reported a turnover exceeding €750 million, with one surpassing the €2 billion mark. As with employment, it should be emphasised that only part of these companies’ turnover derives from biotechnology. According to estimates, approximately €3.1 billion of their turnover is attributable to life-sciences-related activities.

In contrast, dedicated biotechnology companies tend to be relatively small, as reflected in the collective revenue of €879

million generated by 119 companies. The 18 pharmaceutical companies reported a combined revenue of €491 million. Supply, services, sales companies generated a total turnover of €9.8 billion, with core suppliers accounting for €1.1 billion, core service providers €1.9 billion, and core sales and distribution companies €6.8 billion.

Healthy growth

When considering all companies and their respective fields of activity, the sector experienced notable growth in 2020–2023: employment increased by 8% and turnover rose by 30%. For research, development, manufacturing companies, the respective growth figures were 20% for employment and 36% for turnover. Turnover in supply, services, sales grew by 25% while employment decreased by 8% – a decline likely influenced by the impact of the COVID-19 crisis in 2020. Table 3 lists the three largest companies within the branch of research, development, manufacturing.

Vienna’s largest biotechnology and pharmaceutical companies by number of employees

#	Ranked by employees in 2023
1	Takeda
2	Boehringer Ingelheim
3	Octapharma

Table 3: Top 3 biotechnology and pharmaceutical companies active in research, development, manufacturing in Vienna

Dedicated biotechnology companies: bigger, better, faster, more

This category stands out because it is, by definition, the one most focused on biotechnological research and development, placing it at the forefront of technological innovation. The founding of 36 new companies in 2021–2023 – representing 30% of the 119 companies currently active – is a strong indicator of the sector’s vitality and promising future.

Key figures for dedicated biotechnology companies, 2020-2023




Figure 6: Key figures for Vienna’s dedicated biotechnology companies, 2020 and 2023

Figure 6 illustrates this development in detail for dedicated biotechnology companies. The growth figures are striking, reflecting both the expansion of existing companies and the establishment of new ones. The total number of employees increased by 43%, while turnover rose by an impressive 91%.

Young and thriving

Figures 7 and 8 show the dedicated biotechnology companies' size in terms of employees and the age structure, respectively. Figure 7 reveals that most of these companies are rather small: over 71% have fewer than ten employees, and only a handful have 50 or more. This can largely be explained by their age structure, as shown in Figure 8: more than half of the companies were five years old or less in 2023, and a further 19% were six to ten years old.

Employee structure of dedicated biotechnology companies, 2023




Figure 7: Size structure of dedicated biotechnology companies based on staff, 2023, number of observations: 116

Activities including drug development

Figure 9 positions dedicated biotechnology companies within the sector and highlights their specific areas of activity. The data are based on both survey responses and supplementary research. Of the 119 companies, 99 (83%) are active in health/medicine, pursuing activities targeting a broad spectrum of indications. The second most common areas are enabling technologies, reagents, and related fields with 18 companies (15%), followed closely by bioinformatics with 17 companies (14%). Industrial biotechnology accounts for 11 companies (9%), while 7 companies (6%) operate in agricultural biotechnology. Figure 9 also details subcategories within health/medicine activities, based exclusively on survey responses (multiple categories selectable). According to these, cancer (neoplasms), diseases of the blood, blood-forming organs and the immune system as well as infectious and parasitic diseases are centre stage at Vienna's dedicated medical biotechnology companies.

Age structure of dedicated biotechnology companies, 2023, in years




Figure 8: Age profile in years since founding of dedicated biotechnology companies, 2023, number of observations: 116

Clinical pipeline

Drug development goes through a series of stages that must be completed before a discovery can become an approved medicine. Each stage involves significant challenges and risks, with clinical trials being particularly resource-intensive in terms of time and cost. Figure 10 illustrates the distribution of pipeline activities and compares dedicated biotechnology companies to other biotechnology-active and pharmaceutical companies. Each company is counted only once per phase, based on the activities reported in the survey.

Dedicated biotech firms are especially active in preclinical research; only a few have advanced to clinical development. Notably, some of these companies reported having achieved market approval for a drug – an impressive milestone. As anticipated, the broader group of biotechnology-active and pharmaceutical companies is heavily involved in clinical trials and the regulatory processes required for market entry.



Operational focus of biotechnology and pharmaceutical companies in Vienna




Figure 9: Activity-based breakdown of biotechnology and pharmaceutical companies in Vienna with a special focus on dedicated medical biotechnology companies, 2023 (multiple areas of activities and indications possible), number of observations relating to companies active in health/medicine: 52

Companies with drug candidates in the clinical pipeline or approved for the market




Figure 10: Number of Vienna-based companies in the biotechnology and pharmaceutical business sector with drug candidates under development or approved for the market, 2023, numbers of observations: dedicated biotechnology companies: 52, other biotechnology active and pharmaceutical companies: 18

Other biotechnology active companies

By definition, companies classified as “other biotechnology active” also operate in areas beyond core biotechnology, which is why this category can extend into a variety of other industry sectors. In Vienna, this overlap is particularly evident with the traditional pharmaceutical industry. As shown in Tables 2 and 4, this category accounts for the highest number of employees and the largest share of turnover. The survey indicated that about two-fifths originate from biotechnology-related activities (corresponding to about 4,800 employees and €2.9 billion turnover). This category includes some of Austria’s largest biomanufacturing companies, as listed in Table 3, along with one company identified as a spin-off.

Pharmaceutical companies

This category comprises pharmaceutical companies that do not apply biotechnology methods. Those that do are included in the two previously discussed categories (“dedicated” and “other biotechnology active companies”). While the development and production of this type of pharmaceuticals has a long tradition in Vienna and Austria, much of this activity occurs

outside the capital. Nevertheless, Vienna remains home to several large, well-established companies in this segment, which together employ 905 people and generate a combined turnover of €491 million.

Core suppliers in the biotechnology and pharmaceutical business sector

Companies in this category develop, design and supply products intended for use in biotechnology and pharmaceutical research, development, production or distribution. In Austria, larger firms in this segment are typically located in the countryside. Nevertheless, some research-intensive companies are located in Vienna, including one spin-off.

Core service providers in the biotechnology and pharmaceutical business sector

Companies which offer specific services for the life sciences sector are considered in this category, for example consulting services. Some companies are quite large, but they are not necessarily focussing exclusively on biotechnology and pharmaceuticals. Some are also quite research-intensive as exemplified by two spin-offs.

Core sales and distribution companies in the biotechnology and pharmaceutical business sector

Many of the largest multinational biotechnology and pharmaceutical companies have established subsidiaries in Vienna. Core pharmaceutical sales units tend to be quite large, 11 employ more than 75 staff each. Activities in this category go beyond selling and distributing and some companies are also involved in various aspects of development.



We are here for you. The Vienna Business Agency provides advice for business owners in Vienna.

Find the information you
need and get useful advice.

Contact us:
+43 1 25200
info@wirtschaftsagentur.at
viennabusinessagency.at

**vienna
business
agency**



The medical device business sector in Vienna

In 2023, Vienna was home to 297 active medical device companies, employing 10,667 staff members and generating €4.4 billion in revenue. Of these, 28 companies were newly established in 2021–2023, 19 of which are active in research, development, manufacturing, and 9 in supply, services, sales.

Figure 11 compares Vienna’s shares of the medical device business sector to the rest of Austria. Although Vienna maintains a leading position, it is less dominant than in the biotechnology and pharmaceutical business sector (see Figure 5). 46% of Austria’s medical device companies are located in Vienna, along with 36% of employees and 42% of total turnover. While the number of employees increased by 14%, total turnover decreased by 3%, probably due to the circumstances of the COVID-19 pandemic in 2020. In 2021–2023, 28 companies were newly founded, while 22 ceased operations.

Categories and recategorisations

As with the biotechnology and pharmaceutical sector, the medical device sector distinguishes between “dedicated” and “other active” companies, summarised as research, development, manufacturing. The core business of dedicated companies involves the development and/or manufacturing of medical devices; other active companies are those for which medical devices represent only part of their business activities. Additionally, companies engaged in supply, services and sales are classified into three subcategories: core suppliers, core service providers, and core sales and distribution companies.

Table 4 provides detailed data on all companies within Vienna’s medical device business sector. Research for this report identified 39 companies which were active in 2020 but were not included in the previous report. As a result of additions and reassignment, the samples differ from the last report. Accordingly,

Shares of Vienna’s medical device business sector, 2023




Figure 11: Total share of Vienna in Austria’s medical device business sector in terms of number of companies, employees and turnover, 2023

as with Table 2, updated figures for 2020 – reflecting the revised methods and the new sample structure – are also provided in Table 4, including estimated employee numbers and turnover. This establishes a more robust foundation for conducting backward-looking analyses. A full list of companies included in the 2023 sample is provided in the annex (Table 12).

Research, development, manufacturing

89 companies are categorised as active in research, development or manufacturing. Of these, 79 are “dedicated” companies and ten are “other active”. Considering companies that were already active in 2020 but only now included, the total number increased by 15 compared to 2020: 19 companies were founded in 2021–2023, while four ceased operations in Vienna.

	Companies		Employees		Revenues in € m	
	2020	2023	2020	2023	2020	2023
Medical device companies in total	290	297	9,381	10,667	4,512	4,356
Research, development, manufacturing	74	89	1,761	2,198	703	550
Dedicated medical device companies	66	79	1,591	1,954	656	497
Other companies active in medical devices	8	10	170	244	47	52
Supply, services, sales	216	208	7,621	8,469	3,809	3,807
Core suppliers	26	24	921	1,001	452	360
Core service providers	24	24	1,934	2,821	857	844
Core sales and distribution companies	166	160	4,765	4,648	2,500	2,603

Table 4: Key figures for the medical device business sector in Vienna for 2020 and 2023

In 2023, medical device companies with research, development, manufacturing activities in Vienna employed 2,198 people and generated a turnover of €550 million. The three largest companies by employee numbers in operation upon report publication are all classified as dedicated medical device companies, two of them are subsidiaries of

European multinational corporations. These companies are listed in Table 5. Despite a 25% increase in the number of other companies active in medical devices from 8 to 10, both total employee numbers and turnover decreased. This is mainly attributable to one large company that sold its medical device production unit.

Key figures for dedicated medical device companies, 2020-2023




Figure 12: Key figures for Vienna's dedicated medical device companies 2020 and 2023

Dedicated medical device companies: healthy conditions

Figure 12 illustrates the development of medical device companies since 2017. The growth figures are remarkable: both the number of companies and their total workforce have steadily increased, even when taking changes in categorisation and methods into account. Perhaps unexpectedly, total revenue declined, likely due to the exceptional circumstances of 2020.

Total R&D expenditures are estimated to equal about €58 million.

Figure 13 illustrates the size structure of these companies. Similar to the biotechnology companies, most are small: 59% have fewer than ten employees, and 34% have from ten to 49 employees. Moreover, many companies are relatively young, with 43% established within the last five years, as illustrated by Figure 14. However, a significant portion (20%) are longstanding, operating for more than two decades. Five companies are identified as university spin-offs.

Vienna’s largest medical device companies ranked by employees

#	Ranked by employees in 2023
1	Ottobock
2	Dedalus HealthCare
3	BIOMEDICA

Table 5: Top 3 medical device companies active in research, development, manufacturing in Vienna

Employee structure of dedicated medical device companies, 2023




Figure 13: Size structure of dedicated medical device companies based on staff, 2023, number of observations: 76

Age structure of dedicated medical device companies, 2023, in years




Figure 14: Age profile in years since the founding of dedicated medical device companies, 2023, number of observations: 76

Dedicated medical device companies' activities and indications




Figure 15: Dedicated medical device companies within the medical devices business sector, and their areas of activities, 2023 (multiple areas of activities possible), number of observations for companies active in health/medicine: 19

Dedicated medical device companies' fields of activity

Companies in this category engage in research, development and manufacturing across a wide range of fields from medical instruments to software. Figure 15 highlights the two most common areas of activity: software for medicine, telemedicine and e-health, and electromechanical medical devices. Both areas have grown in importance since the previous analysis. Other frequent fields of activity include reusable devices and in-vitro diagnostic devices. Given the increase in both the number of firms and employees, these findings suggest that medical device companies in Vienna are not only growing in number and size but also are successful in addressing market niches across a broad spectrum of unmet medical needs.

Other companies active in medical devices: small but relevant

Although only ten companies fall into the category of other companies active in medical devices, they are by no means insignificant. Half of them have ten or more employees, and seven were founded within the last five years (as of 2023). Their activities include the development of non-pharmaceutical treatments and the production of optical instruments. Two of the ten companies (20%) are identified as university spin-offs.

Supply, services, sales: indispensable

Despite a slight decrease in company numbers (from 216 to 208), companies categorised as core suppliers, core service providers, and core sales and distribution, have developed positively. Total employment within these categories has risen from 7,621 to 8,469 (see Table 4 for details). These companies are essential to the sector, providing critical inputs, offering services such as highly specialised software or regulatory expertise, and handling the distribution of products. Vienna also is an

attractive location for multinational companies with some of the largest companies in this category being subsidiaries of international firms.

Core suppliers: research intensive

Core suppliers provide essential components for end-product manufacturing, such as equipment and production facilities. They employed 1,001 people as of 2023 and generated a revenue of €360 million. Their R&D intensity is underscored by the fact that four of the 24 companies in this category are university spin-offs.

Core service providers

This category has seen a notable increase in employment, rising by 46% from 1,934 to 2,821. These firms include specialists providing hospital management and IT development as a service. Due to the presence of large firms, Vienna is home to the majority of Austria's workforce in this category.

Core sales and distribution companies

This is the largest category within the medical device sector, comprising 160 companies that collectively employ 4,648 people and generate a turnover of €2.6 billion. Operations are primarily centred on sales and distribution of medical devices, and frequently representing foreign firms, including market leaders. Vienna's position as both Austria's capital and a bridge connecting Western, Central and Eastern Europe enhances its appeal as a business location for this type of business.

Facts and figures on research and education in Vienna

Vienna is home to 19 research and education institutions where life sciences play a significant role: six universities, two universities of applied sciences and eleven non-university research institutions. As the figures below demonstrate, Vienna is Austria’s leading scientific centre in this field.

As shown in Figure 16, Vienna hosts around half of Austria’s students and more than half of employees in fields categorised as life sciences. These employees are responsible for 53% of all life-sciences-related publications with an Austrian affiliation. Specifically, these institutions employ 12,634 people and host 34,145 students. Of the 12,634 staff members, an estimated 8,327 are involved in R&D, producing 8,800 scientific articles in 2023, including co-authored publications with other institutes across Austria.

The total budget for life sciences in these institutions is estimated at €1.22 billion, with approximately €310 million originating from third-party funding. Of this, universities account for €918 million in total budget, with €185 million from third-party funding. For universities of applied sciences, the figures are €6 million and €3 million, respectively, while non-university research institutions account for €299 million in total budget, with €121 million from third-party sources. The data presented here focus on organisations with a primary emphasis on research and education and significant activity in the life sciences. Institutions based in Vienna engaging in life sciences research only to a limited extent or whose main focus lies outside science and research-driven academic education – such as museums or state agencies – are not included here. A full list of the organisations in the sample is provided in the annex (Table 13).

Data for the three categories of research and education institutions are given in Table 6. Methodical changes should be considered

when comparing data over years: Unlike in previous years, the data on student numbers and publications in this report is not based on surveys but instead drawn from Austria’s official and comprehensive datasets (see the chapter on the methods for details). For employee figures, estimates for 2020 could not be generated using the new method, therefore the respective column shows data from the previous report. It is important to note that employee numbers refer specifically to life sciences activities, not to the total staff of each institution. The observed decrease in employee numbers is unlikely to represent an actual reduction, but rather results from methodical differences in data estimation and variations in survey participation, especially among larger institutions.

Shares of Vienna’s research and education institutions, 2023




Figure 16: Total share of Vienna in Austria’s research and education institutions in terms of numbers of employees, publications and students, 2023

	Employees		Publications		Students	
	2020*	2023	2020	2023	2020	2023
Total numbers	14,541	12,634	8,559	8,800	32,125	34,145
Universities	12,809	10,388	7,579	7,727	29,266	30,377
Universities of applied sciences	71	178	41	64	2,859	3,768
Non-university research institutions	1,661	2,068	939	1,009	-	-

* As published in the Vienna Life Science Report 2021/22.

Table 6: Key figures for the medical device business sector in Vienna for 2020 and 2023

Universities: Traditional yet future-proof

Most of the universities in Vienna have long-established traditions, and today the University of Vienna and the Medical University of Vienna are, by several measures, the largest Austrian universities in terms of life sciences activities. Other public universities contributing to life sciences include the TU Wien, the University of Natural Resources and Life Sciences, Vienna (BOKU University), and the University of Veterinary Medicine. In contrast to previous reports the Sigmund Freud Private University Vienna (SFU) is now also included in the sample.

Together, these six universities published 7,727 scientific articles in 2023, up from 7,579 in 2020 (with some double-counting in cases of co-authors with multiple affiliations in Vienna). To understand the importance of these universities, consider their output relative to all institutions in Austria: these 7,727 publications account for 47% of Austria's total life-sciences-related publications in 2023. Additionally, Vienna's universities hosted 30,377 students in 2023, up from 29,266 in 2020, representing 44% of all life sciences students in Austria.

Just like university study programmes, core research questions are constantly evolving in Vienna. Over time, greater attention has been given to the One Health approach, which is based on the understanding that human, animal, and environmental health are closely interconnected. Personalised precision medicine has also developed from a forward-looking concept into a central research focus

with the new Eric Kandel Institute – Center for Precision Medicine at its core. Links between laboratory research and clinical application have been strengthened in established fields such as cancer research. And in late 2024, to signify the importance of infectious disease research for public health, five universities established the Ignaz Semmelweis Institute as an alliance against infectious diseases.

Universities of applied sciences: Expanding rapidly

While most universities of applied sciences are located outside Vienna, the city is home to two institutions (twelve overall in Austria) with life sciences departments: FH Campus Wien and UAS Technikum Wien. These institutions are expanding rapidly as indicated by the following figures: from 2020 to 2023, the number of scientific articles published increased by 56%, from 41 to 64, and their student numbers grew by 32%, from 2,859 to 3,768. Although small within Vienna's and Austria's overall innovation system, these universities are playing an increasingly important role in the effective adoption and application of new science-driven approaches, methods and technologies – both at organisations within – and even more beyond academia.

In recent decades, Austrian governments have launched several initiatives to support the establishment of university spin-offs, aiming to enhance knowledge transfer from basic research – primarily conducted at universities – to commercial applications.

Non-university research institutions: Anchors of scientific progress

Vienna's non-university research institutions have shown impressive growth in their research output. From 2020 to 2023, the number of scientific articles published increased by more than 7% from 939 to 1,009. As of 2023, these institutions employ 2,068 people in life sciences, with 1,501 working in R&D. As expected, a substantial proportion of their R&D is third-party funded, accounting for around 41% of their total research activities.

The largest non-university research organisations in Vienna, both in terms of headcount and scientific output, are the Ludwig Boltzmann Gesellschaft (LBG) and the Austrian Academy of Sciences (OeAW). Both have long research traditions: LBG was founded in 1960 and the OeAW was established in 1847. Within

the OeAW, three institutes focus specifically on life sciences in Vienna: the Gregor Mendel Institute of Molecular Plant Biology (GMI), the Institute of Molecular Biotechnology (IMBA), and the Research Center for Molecular Medicine (CeMM). With the establishment of AITHYRA as an institute for biomedical artificial intelligence in collaboration with the Boehringer Ingelheim Foundation in 2024, OeAW reaffirms its position at the forefront of technological innovation in the 21st century. Other institutions in this category include the AIT Austrian Institute of Technology, the Austrian Breast & Colorectal Cancer Study Group (ABCSCG), the Austrian Institute for Chemistry and Technology (OFI), the Research Institute of Molecular Pathology (IMP), the St. Anna Children's Cancer Research Institute (CCRI), and VRVis GmbH.



Other organisations shaping Vienna's life sciences cluster

In addition to companies and research institutions, Vienna is home to 89 other organisations relating to the life sciences sector, according to the latest analysis. Many of these carry out legally mandated tasks in public health and environmental protection and maintain close links to research, development, manufacturing, or marketing and sales. Others offer vital support in areas such as funding, technology transfer, and the overall advancement and strengthening of the life sciences ecosystem. Employment in life sciences reached 2,767 in 2023.

As with the business sectors and the research and education institutions, additions and recategorisations within this group made it necessary to recalculate data for 2020 to enable statistically sound comparisons over time. Compared to the previous report's sample, nine organisations were removed. In contrast, five newly founded organisations and 25 previously existing entities have been added. These dynamics are also reflected in the recalculated data for 2020. For the first time, organisations in this category have been assigned to sub-categories.

Table 7 presents the number of organisations and employees in this category for 2020 (revised estimates) and the updated 2023 figures. Due to the removals described above, the adjusted number of other organisations for 2020 slightly exceeds the 2023 total. Nevertheless, employee numbers increased by 14%, rising from 2,427 to 2,767. These figures represent the number of employees estimated to be directly involved in life sciences. A full list of other organisations included in the 2023 sample is provided in the annex (Table 14).

Governmental entities

With 2,400 employees (16% more than in 2020) across 13 organisations, the sub-category of governmental entities contributes the largest share of the workforce within the other organisations group. Events such as

the COVID-19 pandemic and outbreaks of avian influenza or foot-and-mouth disease clearly highlight their strategic importance in safeguarding public health. Their expertise in regulating market entry of medicinal products, medical devices and IVD as well as environmental matters deserves recognition. In addition to long-established key agencies, this category has a new member: Since 2022, the Austrian Federal Office of Consumer Health (BAVG) oversees the import, transit, and re-import of live animals, food, certain goods, and organic products from third countries.

Special interest groups

This year's statistical analysis includes 50 special interest groups employing an estimated 220 people. Many of the achievements of this group of organisations are made possible through volunteer work, which is not reflected in the figures presented here. Regular changes in this category are common, particularly due to relocations linked to leadership changes within scientific societies. Following the recent launch of Biotech Austria, two new organisations emerged during the current reporting period: Health Pioneers – the Austrian Digital Health Care Association, representing young digital health innovators in Austria, and the BioTech Association (BTA), founded by FH Campus Wien students and alumni to support future biotechnologists by opening doors to industry.

	Numbers of organisations		Employees	
	2020	2023	2020	2023
Other organisations	91	89	2,427	2,767
Governmental entities	12	13	2,063	2,400
Special-interest-groups	53	50	223	220
Funding and support agencies	7	7	40	40
Start-up service providers	3	4	26	31
Additional organisation	16	15	75	76

Table 7: Key figures for other organisations based in Vienna for 2020 and 2023 (number of employees refers to employees who are directly engaged with the life sciences).

Funding and support agencies


Vienna is home to seven key, longstanding funding and support agencies that play a vital role in advancing the life sciences sector. These organisations employ an estimated 40 professionals dedicated to funding life sciences projects and providing strategic support. Among them is Austria Wirtschaftsservice (aws) – the Austrian national promotional bank, which has supported the life sciences in Vienna and across Austria for many years. A flagship initiative is Life Science Austria (LISA), a programme that promotes sector growth by encouraging start-ups, providing financial support, offering consulting and training services, and coordinating international marketing in close cooperation with regional clusters. Another major player is the Austrian Research Promotion Agency (FFG), which launched the “Austrian Life Sciences Programme – Initiative” in 2022 to boost competitiveness in clinical research and Austria’s appeal as a research location. At the regional level, the Vienna Business Agency is a driving force for innovation, while the Austrian Science Fund (FWF) and the Vienna Science and Technology Fund (WWTF) strengthen the scientific foundation of the sector, and the Austrian Business Agency (ABA) provides support for companies that are considering moving to Austria.

Non-profit start-up service providers

Four small non-profit organisations deliver essential services to life sciences start-ups in Vienna, employing a total of 31 specialists. The most recent addition to this group is EIT Health Austria. Established in 2022, this new Co-Location Centre is a key component of EIT Health – part of the European Institute of Innovation and Technology (EIT), a body of the European Union. EIT Health Austria fosters a dynamic innovation environment for healthcare start-ups and SMEs from its Vienna office. Special publicly funded institutions form part of this category, including LISAVienna, Vienna’s central life science cluster platform.

Additional organisations

Fifteen organisations included in the statistics do not fall into any of the previously mentioned sub-categories but remain important contributors to Vienna’s life sciences ecosystem. An estimated 76 employees are active in the sector, primarily engaged in inter- and transdisciplinary work. A notable example is the Future Health Lab, established in 2021, which brings together a diverse group of stakeholders to collaborate on innovative projects focused on the needs of patients and healthcare providers. This category also includes zoos and a museum which, while continuing to focus on their core missions, are increasingly harnessing the potential of their collections and resources for research purposes.



Let's meet Vienna



City of Doers

Vienna is a hotspot for life sciences, research and innovation, and a hub for international encounters. With clear climate goals and a plan to remain one of the world's most liveable cities – today, tomorrow and for future generations.

**Are you ready to launch
your European business
dream?**



Learn more and get to know the ecosystem at vienna.business

ViennaBusiness



LISAvienna: the cluster platform at the heart of Vienna's life sciences ecosystem

For more than 20 years, LISAvienna has been a trusted partner to Vienna's life sciences community, offering information, advice and support for networking, international marketing and strategic growth. The region's innovation ecosystem has matured over time, driven in part by LISAvienna's sustained presence.

As a joint venture of Austria Wirtschaftsservice and the Vienna Business Agency, LISAvienna is Vienna's dedicated life sciences cluster platform. Operating on behalf of the Austrian Federal Ministry of Economy, Energy and Tourism and the City of Vienna, LISAvienna's mission is to position and strengthen Vienna as an innovation-driven and globally recognised location for life sciences.

The platform supports innovative start-ups, SMEs and international companies in biotechnology, pharmaceuticals, medical devices and digital health, developing new products services, and processes in Vienna and bringing these innovations to global markets. LISAvienna facilitates connections between these companies, development partners and key customers, fostering collaboration and accelerating growth.

With its expertise, LISAvienna provides valuable insights and strategic guidance to strengthen the life sciences sector in Vienna, positioning the city as one of Europe's leading innovation hubs.

Tailored support for innovative companies

LISAvienna invites businesses interested in establishing or expanding their operations in Vienna to connect with its cluster management team for personalised advice and networking opportunities. The platform supports innovative companies seeking to establish or scale up their operations in Vienna. LISAvienna facilitates integration into the regional network, helping businesses enhance their product-market fit.

LISAvienna's services

Let LISAvienna guide your journey towards success in Vienna's thriving life sciences ecosystem.

- **Information and advice**
Receive tailored guidance and insights, including tips and connections related to public funding programmes in Austria and Vienna, private equity opportunities, infrastructure and international expansion.
- **Networking and matching**
Benefit from opportunities that enhance networking and knowledge sharing, including links to development partners, key customers and investors.
- **Expertise**
Access in-depth analysis, background information, reports and studies focused on the life sciences sector in Vienna.
- **Marketing activities**
Stay informed with updates on life sciences advances in Vienna, funding opportunities and upcoming events.

Visit this website to learn more:
www.LISAvienna.at

LISAvienna partnering

Tailormade meeting schedules for global players, investors and stakeholders in key markets, including healthcare: contact LISAvienna and meet all the Vienna-based start-ups and SMEs you are interested in – on a single day in Vienna or online.

Life sciences in Vienna: drivers, structures, dynamics

Vienna stands out as a leading innovation hub in the life sciences. The city's success is driven by a combination of key factors: exceptional quality of life, a vibrant academic community, agile start-ups and SMEs catering to niche markets, influential global industry leaders, well-established support programmes and public funding mechanisms, renowned international conferences, high-quality infrastructure and a comprehensive public healthcare system. Its location in the heart of Europe further strengthens Vienna's role as a connector and gateway for international collaboration.

The majority of Austria's life sciences innovators are based in Vienna. The city's significant contribution is a key driver behind the country's excellent position on the European Innovation Scoreboard, where Austria is recognised as a "strong innovator". In sixth place overall, Austria performed above the EU average in ten out of twelve key indicators and is particularly strong in the areas of "attractive research system", "finance and support", and "innovators".

A versatile support ecosystem

Vienna has a long-standing tradition in the life sciences. Its roots go back to the era of Empress Maria Theresa in the 18th century, who laid essential foundations by reforming medical education and advancing scientific institutions. The reorganisation of the medical faculty and her support for what would later become the Austrian Academy of Sciences established enduring structures for academic excellence. Building on this heritage, Vienna has been home to numerous pioneering figures: Ignaz Semmelweis, who introduced antiseptic procedures in obstetrics; Karl Landsteiner, Nobel Laureate and discoverer of blood groups; and Anton Zeilinger, Nobel Prize-winning quantum physicist whose work paved the way for future advances in biomedical imaging and diagnostics. Their achievements highlight Vienna's continued importance as a hub of medical and scientific progress.

Over the decades, the city has developed and sustained initiatives that have driven the industry's upsurge. Education plays a key role in this ecosystem, starting with specialised schools and training programmes for young people and extending to universities. Academic programmes range from Bachelor's to Master's degrees, PhDs and postdoctoral studies, as well as outstanding postgraduate courses and hands-on professional development opportunities. Education, research and innovation are closely connected to a scientific community that covers all facets of the life sciences sector.

To facilitate the application of new knowledge, particularly in the business sector but also by society at large, Vienna offers a wide array of technology transfer and start-up programmes, competitions, incubators, accelerators and science communication initiatives. Funding agencies including the Austrian federal development and financing bank Austria Wirtschaftsservice (aws), the Austrian Research Promotion Agency (FFG) and the Vienna Business Agency provide financing and support for companies. In addition, think tanks and networking initiatives build bridges to the healthcare system and support innovative public procurement. And for over 20 years, LISVienna has been a reliable partner for Vienna's life sciences sector, offering comprehensive and tailored guidance on financing, establishment and relocation, and networking opportunities.

Austrian Business Agency

The first contact for international companies

- > Cost-free support for companies that consider Austria as a business location
- > Labour laws and tax issues
- > Funding and financing possibilities
- > Organising contacts and networking
- > Formalities – from A for access to the labour market to Z for zoning regulations

We simply make it easy!



investinaustria.at/en



© Cavan Images / Westend61

Starting up and growing in Vienna

Founders often report that building an innovative company in Vienna is relatively straightforward. In this vibrant metropolis, it is easy to find talent or attract people from around the globe thanks to its exceptional quality of life, accessibility, affordable cost of living compared to other major cities, and its renowned public transport system. Entrepreneurs benefit from access to outstanding support programmes at a federal and regional level, EU funding opportunities, flexible rental options at incubators like the Startup Labs, and a wealth of on-site expertise in technology, management, marketing, IT and legal affairs. New infrastructure projects by the Vienna Business Agency, such as the Technology Centre in the Seestadt Aspern district and the Life Science Center Vienna, alongside private initiatives, accelerators and incubators, provide space for innovative companies in the region. Besides, QMD

Services is available as a notified body for medical devices and in-vitro diagnostics.

From 2021 to 2024, more than 100 companies in the life sciences sector were established, including 70 dedicated biotechnology, medical device and digital health businesses (see Table 10). This strengthens Vienna's position as a hub for health, smart production and digitalisation. Beyond the traditional focus on medicine, the review period also saw the emergence of promising companies in the bioeconomy and circular economy sectors.

Key indicators of business growth such as financing, revenue and employment figures show that Vienna's life sciences sector has developed well in recent years, beyond the established larger enterprises. Companies have announced financing rounds reaching the triple-digit million-euro range annually (see Table 15), moved into larger laboratory spaces, expanded their facilities and forged new partnerships.

Successful businesses have brought products to market, established branches in other countries, sold or acquired projects, granted or obtained licenses, merged with other companies and undergone acquisitions (see Table 16).

It is undisputed, however, how challenging it is for high-tech companies to secure sufficient capital beyond the start-up phase to take the next steps in their development, especially as regards drug development. In Vienna, too, founding teams often face the need to pivot technologically – initial ideas rarely work out exactly as originally envisioned, and a deeper understanding of market needs frequently leads to shifts. This is where the power of networking kicks in.

World-class destination celebrates innovation

Vienna consistently ranks among the world's top congress destinations, with a strong focus on human medicine conferences that significantly benefit the local scientific and business communities. In 2023, the city recorded 18.9 million overnight stays and accommodation revenue exceeding €1 billion, reaffirming its status as a global tourism leader.

The city continues to draw international attention thanks to groundbreaking achievements by research institutions, start-ups, SMEs and global industry leaders. Events like the ViennaUP Startup Festival, curated by the Vienna Business Agency, highlight the region's innovative spirit and entrepreneurial drive. Initiatives including the ViennaBusiness promotion platform, umbrella brands like Vienna Region, LISA – Life Science Austria and Advantage Austria encourage international audiences to explore Vienna beyond its renowned cultural heritage and picturesque landscapes, showcasing its thriving innovation ecosystem.



On the power of drug development, new platform technologies and innovative services in Vienna

The flourishing regional medical biotechnology sector is characterised by a highly dynamic start-up community, innovative SMEs and several big players with research facilities or manufacturing plants in the city. Science-driven drug discovery and development enrich the global landscape of new approaches to deal with severe diseases.

Despite the risky, time-consuming and expensive nature of drug development, this is still at the core of Vienna's life sciences sector. Today, opening new avenues for patients mostly is a precision medicine endeavour. The enormous increase of knowledge on the molecular basis of diseases means that the "one-size-fits-all" ideal of the past, focusing on drugs targeting an imagined average patient, is no longer feasible for complex diseases such as cancer. In addition, emerging technologies enable us to address conditions where no treatment options were available until recently, and these options even offer the potential to cure certain diseases. Analysing biomarkers helps to select effective drugs or manufacture customised therapies. This all makes monitoring interventions more efficient.

As the understanding of diseases improves, disease models are becoming increasingly precise, bringing the discovery, development and evaluation of diagnostics and therapeutics to a completely new level. In the labs, more sophisticated testing systems that use small amounts of human material, high throughput technologies and machine learning are also reducing and transforming preclinical standards involving in-vivo models.

New concepts and promising technology platforms

Young companies in Vienna are developing a broad range of patentable new technologies. The following examples demonstrate how varied these approaches are:

CRISPR and iPSCs

- **bit.bio discovery:** Harnessing the potential of human iPSCs and the power of CRISPR to transform drug discovery
- **Myllia:** Next-generation tailor-made CRISPR screens in single cells to fast-forward drug discovery

Focus on immunology and cancer

- **Ablevia:** Solutions for quick and selective removal of circulating anti-drug antibodies prior to treatment with modern biotherapeutics and vectors
- **LoopLab Bio:** Synthetic molecular machines ("SelfAmps") address particular cells and tissues to alter their biology and enable new ways to treat immunological disorders
- **Proxygen:** Discovery and development of molecular glue degraders against targets of unmet medical needs across various indications
- **QUANTRO Therapeutics:** A leader in transcriptomic drug discovery using a proprietary and unique technology for time-resolved profiling of transcriptional dynamics, building a first-in-class R&D pipeline for QUANTRO and strategic partners
- **RIANA Therapeutics:** Proprietary phenotypic drug discovery platform to identify innovative drugs targeting challenging protein-protein interactions in cancer

- **Tridem Bioscience:** Discovery and development of innovative active immunotherapies based on the WISIT (WIn the Skin Immune system Trick) technology, first indication: Parkinson's Disease
- **YGION Biomedical:** Individualised treatments for cancer patients that trigger a customised, tumour-specific immune response

Synthetic biology

- **Ribbon Bio:** Long synthetic DNA molecules that enable partners to deliver a new generation of transformative solutions for the health of people and planet
- **VALANX:** Synthetic biology and genetic code expansion for site-specific, fast and cost-effective protein conjugation that powers the development of cutting-edge biologics

Formulation as a game changer

- **NovoArc:** Tetraether lipids for drug formulation, suitable for oral delivery of small molecules and proteins, and parenteral delivery of nucleic acids

Organoids in action

- **a:head bio:** Development of next generation therapeutics for the treatment of brain disorders based on human brain organoids
- **dawn-bio:** Human stem cell-based embryo and implantation model for the discovery and development of compounds to improve in-vitro fertilisation
- **HeartBeat.bio:** Changing the paradigm of cardiac drug development by converging unique human organoid technologies, hardware engineering, and AI

CEBINA

Central European
Biotech Incubator
and Accelerator



Full-Service Approach for Life Science Companies

- State-of-the-art BSL-2 laboratories
- Modern office space, dedicated meeting rooms, conference facilities, and receptionist services
- Personalized business and management support
- Located at the Vienna Biocenter Campus

cebina.eu



Medicinal products in the pipeline

In Vienna, a broad range of innovative medicinal products is being developed. A selection of drug candidates from small molecule drugs to complex biologics and vaccines is introduced here.

- **AOP Health – Targeting rare diseases and critical care:** Drugs for the treatment of Pulmonary Arterial Hypertension, Essential Thrombocythemia and various forms of Tachycardia are in late clinical development and registration stage. In addition, AOP Health investigates a new approach targeting cancer stem cells.
- **BlueSky Immunotherapies – immunotherapy against papillomavirus-induced cancer:** The interferon-inducing viral vector delNS technology makes tumours vulnerable to the immune system, activates defence reactions against cancer and stimulates the production of antiviral molecules. Clinical trials against cervical cancer and head & neck cancer showing significant efficacy and immunogenicity are ongoing.
- **invIOs – Next-generation cancer therapeutics:** An orally available immune-activating small molecule is in preclinical development and has generated strong data on in-vivo inhibition of tumour growth in multiple solid tumour indications. In addition, the EPiC enhancement platform for immune cells has been developed for creating individualised cell therapy treatments that work with the patient's own immune system.
- **Valneva: Lyme Disease, Shigella and Zika vaccine candidates:** The company's single-shot Chikungunya vaccine is approved in several markets including the US, EU, Canada, UK and Brazil, which marked the first approval in an endemic country. Valneva's Lyme Disease vaccine candidate, partnered with Pfizer, is the most clinically advanced programme worldwide and its Shigella vaccine candidate, partnered with LimmaTech, is the world's

most clinically advanced tetravalent Shigella vaccine candidate. A highly purified, inactivated Zika virus vaccine candidate is also in Phase 1 development.

- **Vivaldi Biosciences – Universal influenza vaccine candidate:** DeltaFLU is an advanced, self-adjuvanting influenza vaccine candidate for protection against all influenza type A and B viruses, including seasonal influenza virus strains and emerging strains with pandemic potential. DeltaFLU is administered as a nasal spray.

Innovative technologies, suppliers and services

Developing and manufacturing drugs for global markets is a technology-driven endeavour. Advanced solutions are essential, not only to succeed in manufacturing and ensuring safety, but also to enhance quality, accelerate production and improve sustainability. The creation and delivery of these technologies and services require deep expertise in pharmaceutical manufacturing processes and regulatory standards. Such complex innovations have also emerged in Vienna, as illustrated by the examples below.

- **ABF Pharma | GBA Group:** GMP-certified clinical trial supply services for approved drugs and investigational medicinal products, kit production, labelling, primary and secondary packaging, storage, distribution, QP certification and release, high quality isolation of PBMCs
- **Biomay:** GMP manufacturer of plasmid DNA, mRNA and recombinant proteins – from gene construction to market supply, including personalised and patient-specific plasmid DNA batches in GMP quality, lipid-nanoparticle formulation and aseptic filling
- **enGenes:** Cost-effective microbial biomolecule production services covering plasmid DNA, recombinant proteins and bioconjugates, including lab-scale fed-batch process development and research-grade production

- **Evercyte:** Specialised human primary-like cells for the development of in-vitro test systems enabling standardisation of pre-clinical models and for use as innovative cell factories for production of complex recombinant molecules or extracellular vesicles for clinical applications
- **Holloid:** 24/7, real-time, image-based in-line monitoring using artificial intelligence and digital holographic microscopy; devices for IoT microscopy and software as a service for pharma, food, cosmetics, renewable energy, environmental monitoring and chemical industry
- **Novasign:** Speeding up bioprocess development with hybrid modelling solutions and software using advanced machine learning tools; significant reduction in bioprocess development timelines for both new pharmaceuticals and biosimilars
- **usePAT:** Optimisation of measurements in liquids with ultrasound for improved process control in the industrial environment ranging from chemistry, biotech, pharma, water, wastewater and mining to food and beverages. usePAT helps to generate high-quality, real-time data directly from the process.
- **VelaLabs | Tentamus: GLP/GMP-certified contract laboratory supporting all phases of drug development:** characterisation and QC testing of biomolecules, clinical and non-clinical services up to phase III studies, GMP storage facilities and stability studies
- **VirusSure | Asahi Kasei Life Science:** GMP/ GLP certified CRO specialising in biosafety services for biopharmaceutical products, cell cultured meat and veterinary products. Services include virus/prion clearance studies, cell line characterisation and QC testing, cell and virus banking, long term storage and consultancy.

vivid. flexible.
cutting-edge.

TWENTY ONE
EIN PROJEKT VON BONDI CONSULT

**TwentyOne – more than
just a place to work.**

www.twentyone.immo

Digital health and AI transforming healthcare

The use of software and AI in healthcare is rapidly expanding – ranging from diagnostics and drug development to guideline-compliant treatments, patient flow management, and the documentation and processing of medical information.

Success stories from Vienna contribute significantly to this progress, showcasing exciting innovations. However, there remains vast untapped potential across many medical disciplines and offering intriguing research opportunities, business prospects, and substantial benefits for the healthcare system. This includes cardiovascular health, neurology, immunology and oncology, where promising advancements driven by responsible AI are anticipated in the near future.

From innovation to implementation

Over the past decade, the number of digital health companies in Vienna has grown significantly. Despite technological, regulatory, and financial challenges, several companies have successfully made the transition from development projects to market-ready solutions. A closer look at a selection of examples highlights the diverse range of topics being addressed in Vienna's thriving digital health sector. Highly relevant medical and organisational problems are being solved.

- **Brainhero**: Neurofeedback solution that integrates in-clinic therapy of ADHD and autism with at-home exercises
- **contextflow**: Comprehensive computer-aided detection software for radiologists evaluating lung cancer, ILD and COPD
- **Flinn.ai**: AI-powered platform to automate, manage, and monitor complex regulatory and quality processes in medtech companies, ensuring full compliance with MDR and IVDR
- **ImageBiopsy Lab**: AI-supported imaging intelligence for musculoskeletal diseases that optimises medical workflows and helps turning large amounts of unstructured data into diagnostic evidence
- **Medbee**: Medical guideline knowledge presented briefly, concisely and optimised for smartphones
- **mySugr**: Diabetes management app, blood sugar and carbs tracker, over 6 million registered users worldwide



- **nyra health:** Digital solutions for neurorehabilitation from inpatient to home care, in use at several major healthcare providers in the German-speaking region
- **Platomics:** Automation of regulatory processes and connecting IVD manufacturers and laboratories, accelerating compliance and bringing innovations to patients faster
- **RetInSight:** Pioneer in AI-based image analysis of OCT images for retinal diseases, accurate assessment and treatment evaluation
- **Scarletred:** Certified medical skin imaging software and AI powered analytics with intended use in pre-clinical, clinical and post-market studies

- **XUND:** Guides patients to the right point of care – from prevention to diagnosis and monitoring – to enhance patient care and streamline operations for healthcare providers

Strengthening the foundation for trustworthy AI solutions

Academia is a key driver in developing unbiased and trustworthy AI solutions that can achieve broad acceptance and usage. These drivers include Medical University of Vienna that is striving to become a hub for digital medicine, research and education, TU Wien, University of Vienna, other applied science universities, and institutes at the Vienna BioCenter including AITHYRA. Vienna has succeeded in attracting €150 million from Boehringer Ingelheim Foundation for setting up this new research institute for biomedical AI in 2024.



AUSTROMED represents Austria's medical device businesses – a sector that improves the health and quality of life for millions of people every single day. From high-tech surgical instruments to everyday diagnostic tools, the variety of medical devices is as broad as their impact.

Whether in innovation, logistics, production, or patient care – the versatility of the medical device sector offers countless career paths with purpose.

#branchemitsinn



→ austromed.org/branchemitsinn

AUSTROMED-ACADEMY – KNOWLEDGE THAT MATTERS

The AUSTROMED-Academy offers hands-on training and continuing education tailored to the medical device sector. From procurement and compliance seminars to trainings on behaviour in the operating room, or preparatory tutorials for the qualification examination for trading in medical devices – our programs combine legal expertise with practical relevance.

Available as in-person or in-house sessions –
because learning needs the right format.



→ austromed.org/akademie

In-vitro diagnostics and medical devices made in Vienna

In-vitro diagnostics and medical devices play a crucial role in the preparation and delivery of therapeutic and care services. Beyond that, technological solutions are becoming increasingly important for optimising and accelerating workflows.

Several Viennese companies have successfully established products in key niche markets, while new development projects with significant future potential are emerging. Some of these innovations are also exploring the interface between the healthcare and wellness market sectors.

Diagnostic solutions as a key ingredient for personalised healthcare

Therapy and diagnostics are inseparably linked in medical practice, relying on both established and emerging technologies and methods. Molecular biology approaches have long been standard tools in testing laboratories. Some of the diagnostic tests in use today originate from Vienna, where new products are currently in development as shown by the business focus of the following companies.

- **aitiologic**: AI-powered liquid biopsy for analysing circulating cell-free DNA (cfDNA) for early disease detection and personalised medicine
- **Biomedica**: ELISA immunoassays for clinical research in cardio-renal diseases and bone metabolism, as well as diagnostic tests for cardiac and infectious diseases, distribution of a broad range of additional products for the life sciences, clinics and industry, and hospital PDMS software
- **Biome Diagnostics (myBioma)**: Advancing personalised medicine with microbiome-based technologies for gut microbiome profiling – from improving gut health and overall well-being to predicting the effectiveness of cancer immunotherapies
- **ingenetix**: Design, development and production of real-time PCR-based tests for the detection of pathogens such as bacteria, viruses, fungi and parasites, for applications in human and veterinary medicine
- **MacroArray Diagnostics (MADx)**: Leading developer and manufacturer of allergy and food intolerance tests for diagnostic clinics, laboratories, doctors' practices and hospitals, around 300 different allergens are covered by the IVDR-certified blood test in a single step
- **MetabolizeMe**: Development of groundbreaking health and wellness tracking methods based on cutting-edge metabolite analysis
- **TAmiRNA**: microRNA biomarkers for diagnosis and prediction of diseases and treatment response with a special focus on musculoskeletal, cardiovascular and metabolic diseases
- **Technoclone**: World-leading producer of diagnostics tests, equipment and research products in the area of blood clotting; offers one of the most complete product portfolios on the market
- **ViennaLab Diagnostics**: Easy-to-use in-vitro diagnostic assays for the detection of genetic variants associated with genetic disorders, genetic predispositions, pharmacogenetics, cancer, and the human microbiome

Additive manufacturing bridging research and industry

Research within Vienna's academic landscape forms the foundation for pioneering approaches in additive manufacturing. These are developed and brought to market through a strong network of companies, as the following examples illustrate.

- **Biomotion Technologies:** 3D bioprinters that standardise tissue production for drug discovery and regenerative medicine
- **Cubicure:** Industrial 3D printing solutions with Hot Lithography technology for resilient precision components and digital series production
- **Incus:** Metal 3D printers and materials for medical and dental applications, engineering, electronics, R&D, jewellery
- **Lithoz:** Printers, materials and software for ceramic 3D printing
- **NanoVoxel:** Developing and manufacturing next-generation micro-parts
- **Plasmics:** AI-enabled fused deposition modelling 3D printing for medtech
- **UpNano:** Hub for 2PP 3D printing: From precise prototypes to scalable industrial production

dorda.at

D O R D A

| Health & Life Science Group |



As a trusted sparring partner, we provide the legal **clarity** your innovations require:

- Practical risk assessments & regulatory guidance across all life-science sectors
- Direct access to key stakeholders and early legal trend monitoring
- Specialized advice for pharma, biotech, medical devices, cosmetics and supplements
- Tailored data protection advice and compliance audits (FCPA, anti-bribery)
- Legal support for life-science transactions and start-ups

Empowering future healthcare.

LMG LIFE SCIENCES
AWARDS 2024 EMEA

WINNER

2024

Medtech: Tradition meets innovation

Technological solutions for the healthcare system from Vienna are remarkably diverse, as innovative emerging businesses join the ranks of long-established companies known for their rich history and expanding market presence.

- **AVVie – Angel Valve Vienna:** The Mitral Butterfly (MB) system is a novel solution for patients suffering from mitral regurgitation and subsequent heart failure
- **Ascense Medical:** Transforming aortic disease treatments with advanced compliant vascular devices that maintain aortic function and cardiac efficiency
- **AURIMOD:** Pain relief without medication – VIVO sets a new benchmark in pain treatment with auricular vagus nerve stimulation (aVNS)
- **Carl Reiner:** Manufacturer of jet ventilators for OR and p-BLVTM ventilators for ICU environments, as well as for interventional radiology suites and cardiac cath labs
- **cogvisAI:** Innovative 3D smart sensors for detecting and analysing movements in the room and reliably triggering an alarm in critical situations with the highest privacy protection
- **PIUR IMAGING:** Proprietary sensor technology to provide diagnostic tomographic 3D imaging with any third-party ultrasound device, enabling radiology and telehealth workflows for ultrasound
- **P&F – Products and Features:** Minimally invasive structural heart devices, including solutions to treat mitral and tricuspid regurgitation
- **Schuhfried:** Products for physical medicine and rehabilitation therapies
- **Sumetzberger:** Computer-controlled pneumatic tube solutions with interfaces to automation robots and software systems to achieve full automation in intralogistics, including sorting and storage



Growing bioeconomy network at the heart of Europe

The latest scientific achievements in life sciences not only advance the medical field but also promise to transform all other industries. Vienna's top-tier research institutions and start-ups at the forefront of bio-based innovation contribute significantly to this process.

acib, the Austrian Centre of Industrial Biotechnology was founded in 2010 by Austrian experts in industrial biotechnology. The non-profit research centre develops sustainable, economically and technologically advanced processes for the biotech, pharmaceutical and chemical industries. It strives both for better health and for the bio-based circular economy transition. The centre's primary network partners in Vienna include BOKU University, the University of Vienna, and TU Wien, complemented by FH Campus Wien. Over the years, acib has developed a broad range of technology offers to inspire industry partners. Back in 2019, BOKU University was involved in founding the European Bioeconomy University – a collaboration of leading universities across Europe in the field of bioeconomy that fosters a knowledge-based transformation towards sustainability.

Austria has strong policy frameworks supporting the bioeconomy, including the 2019 Austrian Bioeconomy Strategy and funding programmes from aws, FFG, and the Vienna Business Agency. These initiatives promote sustainability, green tech and bio-based innovations. Vienna's bioeconomy sector is growing: companies are specialising in enzymes, synthetic biology, alternative proteins, green chemistry and on upcycling waste streams from agriculture, food, and forestry for high-value bio-based applications, all of which are aimed at reducing environmental impacts. Young companies addressing bioeconomy topics in the Vienna region include:

- **BioCraft Pet Nutrition:** Meat for pets that doesn't kill other animals, e.g. cultivated

mouse meat for dogs and cats at the same price as premium pet food

- **Blue Planet Ecosystems:** Land-based automated recirculating aquaculture systems for sustainable fish and seafood production, suitable for extreme environments
- **DirectSens:** Next generation biosensors for the food industry and clinical chemistry including measurement of 2-hydroxybutyrate, an early indicator of type 2 diabetes and lactate
- **Evologic Technologies:** Supplying any biological at any scale, anywhere to unlock biologicals for feed and agriculture with manufacturing technology
- **LIVIN farms:** Modular and scalable technology solutions for insect protein production, supplying both the equipment and high-quality Seedlings™ (black soldier fly baby larvae) to convert organic waste into valuable protein and fertiliser
- **Magmatic Bio:** Closing the loop for advanced critical metal regeneration based on the biological repertoire that evolution has forged over billions of years
- **MyPilz:** Fungi for preserving and protecting ecosystems, e.g. to make farmland more resistant to heat, drought and pests while increasing yields
- **Vienna Textile Lab:** High-performance, eco-friendly dyes and pigments derived from microorganisms, making fashion and textile industries more sustainable

Global market leaders value their operations in Vienna

The top 20 global market leaders in biotechnology, pharmaceuticals, and medical devices, ranked by sales in 2023, have established a strategic presence in the Vienna region.

Situated at the heart of Europe and well connected to international rail and flight networks, Vienna offers an ideal location for distribution and sales operations. Vienna also hosts business units specializing in research and development, manufacturing and clinical trials, particularly within the biopharmaceutical sector.

Large corporations represented in Vienna form an important part of the city's economy. Products developed and manufactured here for the global market save lives, assist individuals with disabilities in managing daily life, advance life sciences research, and improve healthcare efficiency.

Decades of excellence in biopharmaceutical manufacturing

Several major corporations are actively investing in their Vienna facilities, as the following examples demonstrate:

Driven by a mission to advance human and animal health, Boehringer Ingelheim has been a vital part of Vienna's scientific and economic landscape for over 75 years. As its first international subsidiary, the Vienna site has grown into one of the German pharmaceutical company's most significant global hubs. In 2024, the Boehringer Ingelheim Regional Center Vienna oversaw operations in 33 countries, generating €1.46 billion in revenue. The company has invested more than one billion euros in expanding its local infrastructure over the past ten years and employs 3,450 people in Austria.

Austria has a longstanding tradition in the development and production of blood plasma-

derived therapies. Each year, more than 20 million litres of blood plasma, obtained through plasmapheresis, are processed into plasma derivatives worldwide. With around 58 litres of plasma collected per 1,000 inhabitants annually, Austria ranks among the global leaders. According to Pharmig, about 20% of the world's plasma supply is fractionated in Vienna. Octapharma and Takeda process a combined total of about 4 million litres of blood plasma annually, and 95% of the products are exported worldwide.

As the largest privately owned and independent plasma fractionator globally, Swiss-based Octapharma produces high-quality human proteins derived from plasma and human cell lines. Its Vienna facility, employing about 1,500 people, plays a pivotal role in production and R&D. To meet growing demand in critical care, haematology and immunology, Octapharma is enhancing efficiency at its facilities while expanding its Vienna operations with a €200 million investment. The entire value chain is covered here: from production and quality assurance to sales and logistics worldwide.

Takeda is committed to delivering innovative treatments: its multiproduct manufacturing facility in Vienna produces plasma-derived therapies and biologics. It boasts over 70 years of expertise in addressing rare and complex diseases, including immunodeficiencies and bleeding disorders. It produces more than 20 drugs in total. The company is investing a nine-figure sum into an advanced, eco-efficient biopharmaceutical R&D „Lab of the Future“ and employs approximately 4,500 people across Austria.

Driving healthcare with premium equipment, digital tools and smart medical devices

Digitization has reshaped every aspect of the life sciences sector in recent years. Leading corporations are leveraging this potential to advance their products, and Vienna-based branches are contributing significantly.

The US-based Danaher corporation, a global leader in life sciences and diagnostics, has invested €10 million to renovate its facilities and bring it up to current sustainability standards. Now accommodating 250 employees, the “Vienna One” site supports R&D, product management, application, sales, training, and services for Danaher companies Leica Microsystems (image analysis), Beckman Coulter Life Sciences (laboratory instruments and software), and Cytiva (tools and services for academia and biopharma).

Dedalus HealthCare is Europe’s market leader in clinical healthcare software headquartered in Milan, Italy. The company’s software integrates artificial intelligence to streamline clinical workflows and enhance patient care. In Austria, a team of 430 employees focuses on advancing a radiology solution, a widely used clinical information system, and on supporting regional customers with the company’s cutting-edge technologies to deliver the best care.

Vienna’s largest medical device company, Ottobock, headquartered in Germany, employs over 600 specialists in the city. The company is dedicated to enabling mobility and independence, and operates R&D and production facilities in Vienna. Each year, Ottobock in Vienna manufactures products to make people worldwide more mobile, which are worth approximately €200 million. Key products developed here include innovative arm and leg prostheses, knee joints, and computer-controlled leg orthoses.

Expanding the view to the broader picture

Global leaders such as MSD, Novartis, Pfizer, Roche, and Thermo Fisher Scientific also play a pivotal role in shaping Vienna’s economic landscape. The lists below provide a broader overview of the market leaders represented in Vienna. Overall, their activities reinforce the city’s status as a hub of innovation and excellence in the life sciences while enhancing its reputation as a leading healthcare metropolis.



Top 20 market leaders ranked by global sales 2023

Biotechnology and pharmaceutical sector

1.	Johnson & Johnson	●
2.	AbbVie	●
3.	Novartis	●
4.	Merck & Co (MSD outside of the U.S. and Canada)	●
5.	Roche	●
6.	Pfizer	●
7.	Bristol Myers Squibb	●
8.	AstraZeneca	●
9.	Sanofi	●
10.	GSK	●
11.	Novo Nordisk	●
12.	Eli Lilly	●
13.	Takeda	●
14.	Amgen	●
15.	Gilead Sciences	●
16.	Boehringer Ingelheim	●
17.	Bayer	●
18.	Viatis	○
19.	CSL	○
20.	Teva Pharmaceutical Industries (via ratiopharm)	●

Source: Pharm Exec: Top 50 Companies (ranked by revenues in 2023)

Medical device sector

1.	Medtronic	○
2.	Abbott Laboratories	○
3.	Danaher (via Leica, Cytiva, Beckman Coulter)	○
4.	Johnson & Johnson	●
5.	Siemens Healthineers	●
6.	Fresenius Medical Care	○
7.	Medline Industries	○
8.	Becton, Dickinson And Company	○
9.	GE Healthcare	○
10.	Stryker Corporation	○
11.	Philips	○
12.	Cardinal Health	○
13.	Baxter	○
14.	Boston Scientific Corporation	○
15.	B. Braun	+
16.	Alcon	○
17.	3M Health Care (Solventum)	○
18.	Fujifilm	○
19.	Zimmer Biomet	○
20.	Intuitive Surgical	○

Source: MD+DI & Qmed: Top 40 Medical Device Companies (ranked by revenues in 2023)

Table 8: The presence of top global market leaders in Vienna

- operating a presence in Vienna
- R&D or manufacturing in Vienna (incl. clinical research)
- ⊕ operating a presence in the Vienna region

Hotspots throughout the City of Vienna – where proximity facilitates innovation


Vienna's life sciences landscape is shaped not only by the impressive facilities of global players employing hundreds of skilled professionals and highly innovative SMEs, but also by the presence of leading academic institutions and university clinics. Their expertise, network and cutting-edge facilities play a strategic role in research and education and for spin-offs and start-ups.

Life sciences are omnipresent in Vienna. Hardly any district remains untouched by activity in this field. In fact, Vienna also has geographical agglomerations known as hotspots. Each life sciences hotspot is unique and, thanks to Vienna's excellent public transport system, it takes less than 45 minutes to travel from one to another. Start-ups appreciate growing in proximity to these academic partners.

Vienna BioCenter

Over the last 30 years, the Vienna BioCenter has established itself as a top biology research centre in Europe, comprising outstanding research institutions conducting innovative research in all areas of life sciences. In addition, a growing number of biotechnology companies are located here. The academic heart of the BioCenter campus includes the Research Institute of Molecular Pathology (IMP) and the Max Perutz Labs – a joint venture of the University of Vienna and the Medical University of Vienna (MedUni Vienna). The largest unit at the Vienna BioCenter is the University of Vienna's Biology Building, hosting its Faculty of Life Sciences and the Centre for Microbiology and Environmental Systems Science (CeMESS). The Austrian Academy of Sciences runs the Gregor Mendel Institute of Molecular Plant Biology (GMI) and the Institute of Molecular Biotechnology (IMBA) on the campus, and, furthermore, the Research Institute for Biomedical Artificial Intelligence (AITHYRA) was founded in 2024. Here, an automated lab designed to run large-scale biological experiments with

minimal human intervention will enable high-throughput pipelines to generate AI-ready datasets to accelerate biomedical innovation. The Vienna BioCenter Core Facilities (VBCF) on the campus offer access to state-of-the-art research infrastructure and scientific services for academic and business users. In addition, the Vienna Business Agency's Startup Labs provide an ideal environment for launching new companies on-site. Incubators and special support initiatives including Cebina with its accelerator programs Danube Labs and Danube Neuro, Health Hub Vienna and INITS play key roles in shaping the BioCenter's dynamic innovation ecosystem.



Medical University of Vienna / AKH campus

Building bridges between research laboratories and patients ranks among the core activities at MedUni Vienna. Closely linked to the University Hospital Vienna (Universitätsklinikum AKH Wien), MedUni Vienna is Austria's flagship in high-end medicine and one of the longest-established medical education and research facilities in Europe. Educating almost 8,600 students, it is the largest medical training centre in the German-speaking countries and is a key player in research and patient care. MedUni Vienna is currently building over 90,000m² of new infrastructure for the medicine of the future, including:

- MedUni Campus Mariannengasse: preclinical research and education
- Eric Kandel Institute – Center for Precision Medicine
- Center for Translational Medicine: from bench to bedside and back
- Anna Spiegel Centre II: room for basic research

The internationally recognised Center for Molecular Medicine (CeMM), that belongs to the Austrian Academy of Sciences, is also a major asset on the campus. In addition, the St. Anna Children's Cancer Research Institute (CCRI) is located nearby, which brings benefits to paediatric patients. Vienna's Medical Hill is also a hub for innovation, generating new technologies, patents, and spin-offs, while actively participating in a wide array of collaborative projects with partners across the global life sciences industry.

BOKU University

The University of Natural Resources and Life Sciences, Vienna (BOKU University) is one of the most advanced life sciences universities in Europe, distinguished by its holistic approach to research and teaching. Starting out in 1872

as a small university specialising in agriculture and forestry, BOKU later became a key driver implementing biotechnology research in Austria. Today, its scientists, students and graduates work on solutions for critical social issues and a sustainable future. BOKU has founded inter- and transdisciplinary competence centres in collaboration with a broad range of partners, including:

- acib – Austrian Centre of Industrial Biotechnology: development of sustainable, economically and technologically advanced processes for the biotechnology, pharmaceutical and chemical industries
- BEST – Bioenergy and Sustainable Technologies: thermochemical, biochemical and syngas technologies for biorefineries, digital methods and solutions, sustainable supply and value cycles
- FFoQSI – Austrian Competence Centre for Feed and Food Quality, Safety and Innovation: solutions for agriculture, sustainable food systems and production, digital transformation of supply chains

Other hotspots of research and teaching

In addition to these outstanding life sciences locations in Vienna, the Austrian Institute of Technology (AIT), TU Wien, two universities of applied sciences (FH Campus Wien and FH Technikum Wien), Sigmund Freud Private University Vienna, and Vetmeduni Vienna are key drivers of innovation in Vienna's life sciences sector and esteemed collaboration partners. In recent years, Zoo Vienna next to Schönbrunn Palace, Vienna's Aqua Terra Zoo, and the Natural History Museum Vienna (NHM) have also intensified their research activities.

Hospitals and university clinics: the core of clinical research

Vienna is Austria's medical innovation hub. Nowhere else in the country is more research conducted, and no other location sees more new approaches to disease prevention, diagnostics, therapy, and care developed and brought into application. Units such as the **Clinical Trials Coordination Centre at the Medical University of Vienna (MedUni Vienna)** and specialised clinical research organisations (CROs) ensure the professional execution of research projects.

Valid clinical data are essential for bringing pharmaceuticals, medical devices, and in-vitro diagnostics to market. In Vienna, this research is primarily conducted at MedUni Vienna and at 26 hospitals, as well as in outpatient settings. MedUni Vienna is serving as a key partner and ranks among the top research institutions in the German-speaking world. International rankings highlight MedUni's extensive expertise in clinical research (Shanghai Global Ranking 2024: 2nd place in clinical medicine in the DACH-region | Newsweek and Statista 2025: 27th of 250 top-ranked hospitals worldwide).

With a population of over 2 million within the city and almost 2.7 million in the metropolitan region, the area provides access to a substantial patient pool. Highly specialised

CROs, consultants, logistics providers, and other support structures also ensure smooth and efficient implementation of clinical research projects.

Facts and figures on clinical trials

In 2023, a total of 295 clinical trials on medicinal products were reported in Austria, the majority of which were industry-sponsored. Most trials were multinational, multicentre studies, with many involving clinics in Vienna. Of these, 30 trials were in Phase I, 67 in Phase II, 181 in Phase III, and 17 in Phase IV of drug development. Austria served as the reporting EU member state (RMS) for 39 clinical trials, placing it among the EU's top ten.



The focus of these clinical trials was primarily on oncology, haematology, autoimmune diseases, neurology/psychiatry, and cardiology. From 2020 to 2022, approximately 4,399 participants were involved in clinical trials in Austria. According to a Pharmig survey covering 74% of the trials, more than 260 clinical trials were conducted in Vienna in 2022. Participant data, provided for 63% of these studies, revealed that over 1,600 participants were enrolled in Vienna in 2022 alone, underscoring the city's key role in Austria's clinical research landscape.

Clinical investigations and performance studies on medical devices and IVDs

In 2023, Austria recorded a total of 72 new applications and notifications for clinical investigations and performance studies involving medical devices and IVDs. Of these, 50 were submitted by commercial sponsors (32 for medical devices and 18 for IVDs), while 22 came from academic sponsors (all related to medical devices). Commercial studies were predominantly focused on high-risk products, whereas academic studies mostly involved low-risk areas.

Official records indicate a decline in the number of submitted clinical investigations and performance studies over the past two years, particularly in the academic sector. This decline can be attributed to two main factors: First, both commercial and academic studies are now subject to the same fees under the new regulatory regime. Second, the regulations have increased the qualitative and formal requirements for study approvals and notifications. Despite this, the number of performance studies for IVDs in the commercial sector remains high. This trend is likely a result of stricter requirements for marketing IVDs in the EU as introduced by the In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR).

New Center for Translational Medicine

A new Center for Translational Medicine at MedUni Vienna is being established in Vienna to strengthen the connection between basic science and clinical practice and to jointly develop new research and clinical trial projects. The centre integrates the entire process – from experimental laboratory research to Phase I/II clinical trials – under one roof, serving as a hub for knowledge exchange.

State-of-the-art core facilities provide easy access to advanced high-end equipment and cutting-edge technologies. These include a GMP facility for cell therapy, radiopharmacy, biologics, a biobank, and a clinical centre for Phase I and II studies with dedicated patient and participant facilities. This infrastructure will ensure that new research findings are rapidly translated into therapies, particularly for cardiovascular and immunological diseases as well as cancer. Additionally, it will foster the development of modern diagnostics and innovative therapeutic strategies.



26 Hospitals in Vienna

Vienna Health Association

- Donaustadt Hospital
- Favoriten Hospital
- Floridsdorf Hospital
- Hietzing Hospital
- Landstraße Hospital
- Ottakring Hospital
- University Hospital Vienna (AKH Wien)

Private hospitals

- Confraternität Private Hospital
- Döbling Private Hospital
- Goldenes Kreuz Private Hospital
- Rudolfinerhaus
- Sanatorium Hera
- Sanatorium Liebhartstal
- Wiener Privatklinik Hospital

Denominational hospitals

- Barmherzige Schwestern Krankenhaus Wien
- Göttlicher Heiland Krankenhaus
- Herz-Jesu Krankenhaus Wien
- Orthopädisches Spital Speising Wien
- St. Josef Krankenhaus
- Evangelisches Krankenhaus
- Franziskus Spital
- Krankenhaus der Barmherzigen Brüder

Other hospitals

- Anton-Proksch-Institute
- Hanusch Hospital, ÖGK
- St. Anna Children's Hospital, Red Cross
- Trauma Care Center Vienna, AUVA



Selected partners for clinical research

Medical University of Vienna:

- **Research clusters** in immunology, cancer, medical neuroscience, cardiovascular medicine and medical imaging
- **Special expertise** also in personalised precision medicine, digital medicine including AI and ML, infection research, rare and undiagnosed diseases, transplantation, metabolism
- **Clinical Trials Coordination Centre**
www.meduniwien.ac.at/kks
- **Center for Medical Physics and Biomedical Engineering**
<https://mpbmt.meduniwien.ac.at/en/>
- **Center for Translational Medicine**
<https://bauprojekte.meduniwien.ac.at/en/zentrum-fuer-translazionale-medizin/zentrum-fuer-translazionale-medizin/>

Vienna Health Association

www.gesundheitsverbund.at

Vinzenz Group Vienna

www.vinzenzgruppe.at

OKIDS Network for paediatric medicinal product research in Austria

www.okids-net.at

Austrian Breast & Colorectal Cancer Study Group (ABSCG)

www.abcsrg.org

The Austrian LEAD Study: Lung – hEart – sociAI – body

www.leadstudy.at

Report

2024

Life Science
Austria

A detailed analysis
of nation-wide data
is provided in the

**Life Science Report
Austria 2024**

www.lifescienceaustria.at

Methods

Survey and definitions

The data presented in this report are based on the “Life Science Report Austria – 2024” by considering only those life science organisations which are located in Vienna (the Austrian report is available from <https://www.lifescienceaustria.at/>). In this section, a summary regarding definitions, data sources, and calculations is given. Revenue values are shown in nominal terms and are not inflation-adjusted. For details on the methods, please refer to the Austrian report.

In this report, “life sciences” is used as an umbrella term encompassing the economic sectors of biotechnology (not limited to medical applications), the pharmaceutical industry, and the medical device field, including digital health, as well as the related academic disciplines fueling these sectors.

The present report distinguishes between four major categories and several sub-categories of organisations:

1. Biotechnology and pharmaceutical business sector
 - a. Research, development, manufacturing
 - i. Dedicated biotechnology companies
 - ii. Other biotechnology active companies
 - iii. Pharmaceutical companies
 - b. Supply, services, sales companies
 - i. Core suppliers in the biotechnology and pharmaceutical business sector
 - ii. Core service providers in the biotechnology and pharmaceutical business sector
 - iii. Core sales and distribution companies in the biotechnology and pharmaceutical business sector
2. Medical device business sector
 - a. Research, development, manufacturing
 - i. Dedicated medical device companies
 - ii. Other companies active in medical devices
 - b. Supply, services, sales companies
 - i. Core suppliers in the medical device business sector
 - ii. Core service providers in the medical device business sector
 - iii. Core sales and distribution companies in the medical device business sector
 - iv. Research and education institutions
3. Universities
 - i. Universities of applied sciences
 - ii. Non-university research institutes
4. Other organisations
 - i. Governmental entities
 - ii. Special-interest-groups
 - iii. Funding and support agencies
 - iv. Start-up service providers
 - v. Additional organisations

These categories are intended to provide a clearer understanding of the core of the life sciences sector. However, they represent only part of the sector’s structure and should not be viewed as entirely disjunct.

Given that some companies operate across multiple fields, certain overlaps exist between these categories, thus allowing for a degree of flexibility in the categorisation of organisations. For methodical consistency, each organisation has been assigned to a single category. Data related to three additional categories – “other suppliers”, “other service providers” and “other sales companies” – are included in the Austrian Life Sciences Directory (lifesciencedirectory.at) but not in the statistical analysis presented in this report. This should be considered when interpreting the findings.

From June to September 2024, a survey was conducted by WPZ Research on behalf of Austria Wirtschaftsservice (aws) and the Austrian Federal Ministry of Economy, Energy and Tourism. Table 9 provides the survey statistics. The data in this report are based on this survey, the company database “Aurelia” as provided by Bureau van Dijk, the university database “uni:data” as provided by the Austrian Federal Ministry of Education, and additional research. Estimations for 2020 reflect several recategorisations and additions of companies and other organisations, as well as methodical changes. They are not directly comparable to the numbers given for 2020 in the last report.

Extensive investigations identified an additional 106 companies founded in 2020 or earlier that are also active in the life sciences sector. 83 companies were established in 2021- 2023 while 53 ceased operations, resulting in a net increase of 30 companies for 2023 or almost 5%. Adjustments to the categorisation of research and education institutions in life sciences led to a net increase of one institution. In the case of other organisations, 10 were removed, while 26 existing and five newly established organisations were added resulting in a net increase of 21 entities in the sample.

	Requested	Answered	Response rate
Life science companies	645	150	23.26%
Biotechnology and pharmaceutical business sector	348	101	29.02%
Research, development, manufacturing in the biotechnology and pharmaceutical business sector	174	76	43.68%
Supply, services, sales in the biotechnology and pharmaceutical business sector	174	25	14.37%
Medical device business sector	297	49	16.50%
Research, development, manufacturing in the medical devices business sector	89	30	33.71%
Supply, services, sales in the medical device business sector	208	19	9.13%
Research and education institutions	19	9	47.37%
Other organisations	86	17	19.77%

Table 9: Survey statistics

References

BASG: Klinische Prüfungen mit Medizinprodukten und Leistungsprüfungen von In-Vitro-Diagnostika – Statistik 2023

https://www.basg.gv.at/fileadmin/redakteure/06_Gesundheitsberufe/Klinische_Studien/MPG/BASG_CLTR_KP_MPG_Statistik_2023_DE_v1_2024-08.pdf

EC: European Innovation Scoreboard 2024 – Country Profile Austria

https://ec.europa.eu/assets/rtd/eis/2024/ec_rtd_eis-country-profile-at.pdf

Economist: The Global Liveability Index

<https://www.eiu.com/n/campaigns/global-liveability-index-2024/>

Hospitals in Vienna

<https://www.wien.gv.at/gesundheit/einrichtungen/index.html>

Life Science Report Austria 2024

https://www.lifescienceaustria.at/fileadmin/user_upload/Life_Science_Report_Austria_2024.pdf

MD+DI & Qmed: Top 40 Medical Device Companies (ranked by revenues in 2023)

<https://www.mddionline.com/business/top-40-medical-device-companies>

Medical University of Vienna: Major construction projects

<https://bauprojekte.meduniwien.ac.at/>

Mercer: Quality of Living City Ranking

<https://www.mercer.com/insights/total-rewards/talent-mobility-insights/quality-of-living-city-ranking/>

Monocle: Quality of Life Survey

<https://monocle.com/affairs/urbanism/quality-of-life-survey-2024/>

Newsweek and Statista: World's Best Hospitals 2025

<https://www.newsweek.com/rankings/worlds-best-hospitals-2025>

Pharm Exec: Top 50 Companies (ranked by revenues in 2023)

<https://www.pharmexec.com/view/2024-pharm-exec-top-50-companies>

Pharmig Facts & Figures 2024: Pharmaceuticals and Healthcare in Austria

https://www.pharmig.at/media/pyplqsqt/2024-pharmig_facts-figures_e.pdf

Shanghai Ranking 2024: Clinical Medicine

<https://www.shanghairanking.com/rankings/gras/2024/RS0401>

Statistics Austria, R&D in the business enterprise sector 2021

<https://www.statistik.at/en/statistics/research-innovation-digitalisation/research-and-experimental-development-rd/rd-in-all-economic-sectors/rd-in-the-business-enterprise-sector>

Vienna BioCenter

<https://www.viennabiocenter.org/>

Vienna in Figures 2024

<https://www.wien.gv.at/statistik/publikationen/wien-in-zahlen.html>

Vienna Meeting Industry Report 2023

<https://meeting.vienna.info/en/who-we-are-services/vienna-meeting-industry-report>

(Date of last access: May 27, 2025)

Advancing Austrian life science at the heart of Europe

Find out more
about our excellence

www.lifescienceaustria.at



Find your right partner in Austria

www.lifesciencesdirectory.at



LISA 
LIFE SCIENCE AUSTRIA

Annex

New life science companies in Vienna

		Dedicated biotech company	Biotech active company	Pharma company	Supplier (biotech/pharma)	Service provider (biotech/pharma)	Sales company (biotech/pharma)	Dedicated medical device company	Company active in medical devices	Service provider (medtech)	Sales company (medtech)
2021	ADvantage Therapeutics GmbH	●									
2021	ALLECTRIC GmbH AT							●			
2021	Alpstar Medical Products GmbH						●				
2021	Ascense Medical GmbH							●			
2021	BioCraft Pet Nutrition GmbH	●									●
2021	cannmedic GmbH										
2021	CellElectric Biosciences GmbH	●									
2021	Cutanos GmbH	●									
2021	Evobright GmbH	●									
2021	Exactech EÖG GmbH								●		
2021	Fermify GmbH	●									
2021	FUJIFILM Austria GmbH										●
2021	Galapagos Biopharma Austria GmbH						●				
2021	Health Force GmbH							●			
2021	HeartBeat.bio AG	●									
2021	HöR-AKUSTiK DöBLiNG GmbH								●		
2021	imd BIOTECH GmbH	●									
2021	Intuitive Surgical Österreich GmbH										●
2021	invlOs GmbH	●									
2021	Luna-IP GmbH								●		
2021	MAG-LAB GmbH	●									
2021	Moderna Austria GmbH						●				
2021	MY Wasseranalytik GmbH		●								
2021	NDx Bio GmbH	●									

		Dedicated biotech company	Biotech active company	Pharma company	Supplier (biotech/pharma)	Service provider (biotech/pharma)	Sales company (biotech/pharma)	Dedicated medical device company	Company active in medical devices	Service provider (medtech)	Sales company (medtech)
2021	New Path Bio GmbH	●									
2021	NovoArc GmbH	●									
2021	Proglycan GmbH	●									
2021	QC3 GmbH	●									
2021	QUBICON AG	●									
2021	Revo Foods GmbH		●								
2021	Rockfish Bio AG	●									
2021	Roots Health GmbH							●			
2021	Rosta Biotech GmbH	●									
2021	Seagen Austria GmbH						●				
2021	Stelopharm GmbH						●				
2021	TETRAGON Braille Systems GmbH							●			
2021	VTL GmbH Vienna Textile Lab	●									
2022	1BillionLives GmbH							●			
2022	Altus Biolabs GmbH	●									
2022	Aspire Innova GmbH	●									
2022	BeiGene Austria GmbH						●				
2022	Brightmind.AI GmbH							●			
2022	CAATS Service GmbH							●			
2022	CompreVie In Vitro Diagnostics GmbH	●									
2022	HearO GmbH							●			
2022	Holloid GmbH	●									
2022	Illumina Austria GmbH			●							
2022	Impairment Analytics DH2S GmbH							●			
2022	Ipsen Pharma Austria GmbH						●				
2022	Jazz Pharmaceuticals Austria GmbH						●				

		Dedicated biotech company	Biotech active company	Pharma company	Supplier (biotech/pharma)	Service provider (biotech/pharma)	Sales company (biotech/pharma)	Dedicated medical device company	Company active in medical devices	Service provider (medtech)	Sales company (medtech)
2022	Körper Pharma Austria GmbH					●					
2022	MSP Medizintechnik GmbH										●
2022	MyPilz GmbH	●									
2022	NanoVoxel GmbH				●						
2022	OMV Green Energy GmbH		●								
2022	psimistri GmbH							●			
2022	Regenera GmbH	●									
2022	VERDI Solutions GmbH	●									
2022	YGION Biomedical GmbH	●									
2023	aitiologic GmbH	●									
2023	Albius Sciences (Austria) GmbH	●									
2023	Apellis Austria GmbH						●				
2023	Aurovir Pharma GmbH			●							
2023	bespark bio GmbH	●									
2023	Creative Medical GmbH							●			
2023	dawn-bio GmbH	●									
2023	DEXCOM INTERNATIONAL LIMITED - Zweigniederlassung Österreich										●
2023	DEZIMAL GmbH							●			
2023	Engelhard Arzneimittel GmbH & CoKG - Zweigniederlassung Österreich					●					
2023	HARPS Europe Manufacturing GmbH - Zweigniederlassung Wien								●		
2023	HARPS Europe GmbH										●
2023	HD Immune GmbH	●									
2023	lablife gmbh					●					

		Dedicated biotech company	Biotech active company	Pharma company	Supplier (biotech/pharma)	Service provider (biotech/pharma)	Sales company (biotech/pharma)	Dedicated medical device company	Company active in medical devices	Service provider (medtech)	Sales company (medtech)
2023	LoopLab Bio GmbH	●									
2023	Magmatic Bio GmbH	●									
2023	MED Technologies GmbH										●
2023	Medivs Pharma GmbH										●
2023	MiiCare Austria GmbH										●
2023	myResQ GmbH							●			
2023	nagene GmbH	●									
2023	OFS Lipid Legends GmbH		●								
2023	PassionBio e.U.				●						
2023	RIANA Therapeutics GmbH	●									
2023	speak23 GmbH									●	
2023	Valeriot GmbH							●			
2024	Align Technology Austria GmbH										●
2024	All But Sugar GmbH Smiling Food	●									
2024	Alpine Biolabs FlexCo	●									
2024	ARIVA Med GmbH	●									
2024	Biomotion Technologies FlexCo							●			
2024	CBRS Center for Bioinformatic Research and Services e.U.	●									
2024	Confideck GmbH							●			
2024	Desitin Pharma Austria GmbH						●				
2024	Discovery Evolution FlexCo	●									
2024	Elio Technologies FlexCo	●									
2024	Exalt FlexCo	●									
2024	Fragrami GmbH	●									
2024	Freundeskreis GmbH	●									
2024	Glycanostics GmbH	●									

		Dedicated biotech company	Biotech active company	Pharma company	Supplier (biotech/pharma)	Service provider (biotech/pharma)	Sales company (biotech/pharma)	Dedicated medical device company	Company active in medical devices	Service provider (medtech)	Sales company (medtech)
2024	MetabolizeMe GmbH	●									
2024	PathoCap GmbH	●									
2024	Regeneron Austria GmbH						●				
2024	Supercoiled GeneTx GmbH	●									
2024	TiliaHealth FlexCo							●			
2024	Turn-Motion FlexCo							●			
2024	ViVerita Discovery FlexCo	●									
2024	WaveVision GmbH							●			

Table 10: Life science companies founded in 2021, 2022, 2023 and 2024 in Vienna - this list is not exhaustive.

Biotechnology / pharmaceutical companies in Vienna covered by the statistical analysis

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
1 A Pharma GmbH						●
a:head bio AG	●					
ab&cd innovations GmbH	●					
ABACUS Medicine Austria GmbH						●
Abbott GmbH						●
AbbVie GmbH		●				
ABF Pharmaceutical Services GmbH					●	
Ablevia biotech GmbH	●					
ADvantage Therapeutics GmbH	●					
Advanz Pharma Österreich GmbH						●
Affiris CVD GmbH	●					
AGEA Pharma GmbH						●
aitiologic GmbH	●					
Albius Sciences (Austria) GmbH	●					
Alexion Pharma Austria GmbH						●
Algonist Biotechnologies GmbH	●					
AlgOss Biotechnologies GmbH	●					
Alliance Medical BSM GmbH			●			
Almirall GmbH						●
Alnylam Austria GmbH						●
Alpstar Medical Products GmbH						●
Altus Biolabs GmbH	●					
AMGEN GMBH		●				
Amomed Pharma GmbH						●

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
Angelini Pharma Österreich GmbH						●
AnYxis Immuno-Oncology GmbH	●					
AOP Orphan Pharmaceuticals GmbH			●			
APEIRON Biologics AG	●					
APEIRON Respiratory Therapies GmbH	●					
Apellis Austria GmbH						●
APEPTICO Forschung und Entwicklung GmbH	●					
Aposcience AG	●					
Arcana Arzneimittel GmbH						●
Aristo Pharma Österreich GmbH						●
Aspire Innova GmbH	●					
Astellas Pharma Ges.m.b.H.			●			
AstraZeneca Österreich GmbH		●				
Astro-Pharma Vertrieb und Handel von pharmazeutischen Produkten GmbH						●
Attoquant Diagnostics GmbH	●					
Aurovir Pharma GmbH			●			
Austrianni GmbH	●					
BASF Österreich GmbH				●		
Baxalta Innovations GmbH		●				
Baxter Healthcare GmbH						●
Bayer Austria Gesellschaft .m.b.H		●				
BeiGene Austria GmbH						●
Bencard Allergie GmbH						●
Bender MedSystems GmbH		●				
bespark bio GmbH	●					
BioCraft Pet Nutrition GmbH	●					
Biogen Austria GmbH		●				

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
BIOLAB Laborgeräte Handelsgesellschaft m.b.H.				●		
Biomay AG	●					
Biomedical International R+D GmbH	●					
Biomedizinische Forschung & Bio-Produkte GmbH	●					
BioNTech R&D (Austria) GmbH	●					
Bioplant Research & Development GmbH	●					
Biosynth GmbH	●					
Biotest Austria GmbH						●
Biozym Biotech Trading GmbH				●		
BIT BIO Discovery GmbH	●					
Bluefish Pharma GmbH						●
BlueSky Immunotherapies GmbH	●					
Boehringer Ingelheim RCV GmbH & Co KG		●				
Bracco Österreich GmbH						●
Bristol-Myers Squibb GmbH		●				
C. Brady GmbH & Co KG			●			
CALYXHA Biotechnologies GmbH	●					
CEBINA GmbH					●	
Celerion Austria GmbH					●	
CellEctric Biosciences GmbH	●					
Celltrion Healthcare Austria GmbH						●
ChanPharm GmbH		●				
Chemengineering International GmbH					●	
Chiesi Pharmaceuticals GmbH						●
Circe Biotechnologie GmbH	●					
CIS Clinical Investigation Support Pharmaforschung Gesellschaft m.b.H.					●	
Clinical Trials Management GmbH					●	

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
CompreVie In Vitro Diagnostics GmbH	●					
COVIN Pharmavertriebs GmbH						●
Covirabio GmbH	●					
CPI Chemikalienhandelsgesellschaft m.b.H.				●		
CSL Behring GmbH						●
Currex Pharma GmbH						●
Cutanos GmbH	●					
Cyto-Care.eu GmbH				●		
D&A Pharma GmbH						●
Daiichi Sankyo Austria GmbH		●				
Datamedrix GmbH					●	
dawn-bio GmbH	●					
Delta 4 GmbH	●					
Dermapharm GmbH						●
DIPHA GmbH			●			
DONAUCHEM GmbH				●		
Dr. Falk Pharma Österreich GmbH						●
Dr. Muin Pharma GmbH			●			
DREHM Pharma GmbH					●	
Ecolab GmbH				●		
Eisai GesmbH		●				
Elanco Austria GmbH						●
Eli Lilly Gesellschaft m.b.H.		●				
Elisabeth Schubert Soft-Line chemisch-technische Produkte Nea Warenvertriebsges. m.b.H.						●
Eli-Tec pharmazeutischer Großhandel Mag. Ernst Baurek GmbH						●
emergentec biodevelopment GmbH	●					

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
Engelhard Arzneimittel GmbH & CoKG - Zweigniederlassung Österreich						●
enGenes Biotech GmbH	●					
Engler Steritech GmbH				●		
EQ-BOKU (Equipment-BOKU) - GmbH					●	
Eurofins Genomics AT GmbH	●					
Europlasma GmbH		●				
EveliQure Biotechnologies GmbH	●					
EVER Pharma AT GmbH						●
Evercyte GmbH	●					
Evobright GmbH	●					
Evologic Technologies GmbH	●					
Exscientia GmbH	●					
F. Trenka Chem.pharm. Fabrik Gesellschaft mbH						●
F2G Biotech GmbH	●					
F4-Pharma Ges.m.b.H.	●					
FAVEA Handel mit pharmazeutischer Technologie GmbH				●		
Fermify GmbH	●					
Ferring Arzneimittel Gesellschaft m.b.H.						●
first pharma J.M.T. GmbH						●
Fortrea Austria GmbH					●	
G.ST Antivirals GmbH	●					
Galapagos Biopharma Austria GmbH						●
Galderma Austria GmbH						●
GC Genomics GmbH					●	
Germania Pharmazeutika GmbH			●			
Gilead Sciences GesmbH		●				

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
Gilvasan Pharma GmbH						●
GlaxoSmithKline Pharma GmbH		●				
GLOBOPHARM Pharmazeutische Produktions- und Handelsgesellschaft mbH		●				
Gouya Insights GmbH & Co KG					●	
Grünenthal Österreich GmbH						●
Guerbet Großhandel mit pharmazeutischen Produkten Ges.m.b.H.						●
HAL ALLERGY Handels-GmbH						●
HAPLOGEN Bioscience GmbH	●					
HD Immune GmbH	●					
HeartBeat.bio AG	●					
Herba Chemosan Apotheker-AG						●
Hermes Arzneimittel Vertriebsgesellschaft mbH						●
Hexal Pharma GmbH						●
HG Pharma GmbH	●					
HIPRA Deutschland GmbH - Zweigniederlassung Österreich						●
Holloid GmbH	●					
HOOKIPA Biotech GmbH	●					
HVD Life Science Vertriebs GmbH				●		
Hypericum LifeScience GmbH	●					
ICON Clinical Research Austria GmbH					●	
IDEOGEN GmbH						●
IDEPS GmbH				●		
IHCS Arzneimittel Vertriebs GmbH						●
Illumina Austria GmbH				●		
IMCD South East Europe GmbH						●
imd BIOTECH GmbH	●					

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
IMPROCESS GmbH					●	
Incyte Biosciences Austria GmbH						●
InfectoPharm Arzneimittel und Consilium GmbH						●
ingenetix GmbH	●					
Interpharm ProduktionsgmbH			●			
Intervet GesmbH	●					
invIOs GmbH	●					
Ipsen Pharma Austria GmbH						●
IQVIA Information Solutions GmbH					●	
IQVIA RDS Eastern Holdings GmbH					●	
IQVIA RDS GesmbH					●	
ISOtopic solutions e.U.					●	
Janssen-Cilag Pharma GmbH		●				
Jazz Pharmaceuticals Austria GmbH						●
Jesmond BioScience GesmbH					●	
JLP Health GmbH	●					
Johnson & Johnson Gesellschaft m.b.H.						●
Jungbunzlauer Austria AG		●				
KARMED HandelsgesmbH						●
Kasel GmbH				●		
Kiora Pharmaceuticals GmbH	●					
Körber Pharma Austria GmbH					●	
KRKA Pharma GmbH						●
Kwizda Agro GmbH		●				
Kwizda Pharma GmbH			●			
Kwizda Pharmahandel GmbH						●
Kyowa Kirin Austria GmbH						●

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
LabConsulting GmbH				●		
LABDIA Labordiagnostik GmbH	●					
lablife gmbh					●	
LEICA Mikrosysteme GmbH				●		
Lenus Pharma GesmbH			●			
LEO Pharma GmbH						●
Lexogen GmbH	●					
LifeNet Health Europe GmbH						●
Lisalis GmbH					●	
LIVIN farms AgriFood GmbH	●					
loopbio gmbh				●		
LoopLab Bio GmbH	●					
Lundbeck Austria GmbH			●			
MAG-LAB GmbH	●					
Magmatic Bio GmbH	●					
Mark53 GmbH	●					
Marwian GmbH				●		
MayLab Analytical Instruments GmbH				●		
Medibena Dr. Peter Bencur e.U.				●		
Medicopharm GmbH						●
MedLance Pharma GmbH						●
Medpace Austria GmbH						●
Merck Chemicals and Life Science GesmbH		●				
Merck GesmbH						●
Merck Sharp & Dohme GmbH		●				
Merz Consumer Care Austria GmbH						●
Merz Pharma Austria GmbH						●

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
Microsynth Austria GmbH	●					
Miti Biosystems GmbH	●					
Mitsubishi Tanabe Pharma GmbH - Zweigniederlassung Österreich						●
Moderna Austria GmbH						●
MoNo chem-pharm Produkte GmbH			●			
Mundipharma Gesellschaft m.b.H.						●
MY Wasseranalytik GmbH		●				
Myelopro Diagnostics and Research GmbH	●					
My-IGeL Arzneimittel Produktion & Vertrieb GmbH						●
Myllia Biotechnology GmbH	●					
MyPilz GmbH	●					
Nabriva Therapeutics GmbH	●					
nagene GmbH	●					
NanoVoxel GmbH				●		
Nascyma Pharma GmbH						●
NBS-C BioScience & Consulting GmbH	●					
NDx Bio GmbH	●					
New Path Bio GmbH	●					
Norgine Pharma GmbH						●
Noscat GmbH						●
Novartis Pharma GmbH		●				
Novasign GmbH				●		
Novo Nordisk Pharma GmbH		●				
NovoArc GmbH	●					
Nuvonis Technologies GmbH	●					
Octapharma Handelsgesellschaft mbH						●
Octapharma Pharmazeutika Produktionsgesellschaft mbH		●				

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
OFS Lipid Legends GmbH		●				
OKIDS GmbH					●	
OmniVision GmbH						●
OMV Green Energy GmbH		●				
Opella Healthcare Austria GmbH						●
Organon Austria GmbH						●
ORION Pharma (Austria) GmbH						●
ÖRK Einkauf und Service GmbH						●
P4 Therapeutics GmbH	●					
PALL AUSTRIA Filter GmbH				●		
PassionBio e.U.					●	
Perrigo Österreich GmbH						●
PEZZ life GmbH	●					
Pfizer Corporation Austria GmbH		●				
Pharma Mar Ges.m.b.H.						●
pharmaand GmbH						●
pharmacom Handels GmbH						●
PharmaPuls GmbH						●
Pharmaselect Handels GmbH						●
PHARMOSAN Handelsgesellschaft m.b.H.						●
PHOENIX Arzneiwarengroßhandlung GmbH						●
PINT-PHARMA Gesellschaft m.b.H.						●
Pivaris BioScience GmbH	●					
PLANTA Naturstoffe Vertriebsges.m.b.H.	●					
Platomics GmbH	●					
Pregenerate GmbH	●					
ProFem GmbH		●				

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
Proglycan GmbH	●					
Proxygen GmbH	●					
PTC Therapeutics Austria GmbH						●
QC3 GmbH	●					
QIAGEN GmbH - Zweigniederlassung Österreich				●		
QMD Services GmbH					●	
QUANTRO Therapeutics GmbH	●					
QUBICON AG	●					
ratiopharm Arzneimittel Vertriebs-GmbH						●
Reckitt Benckiser Austria GmbH						●
Regenera GmbH	●					
Revo Foods GmbH		●				
RIANA Therapeutics GmbH	●					
Ribbon Biolabs GmbH	●					
Richard Bittner AG			●			
Rieger Industrievertretungen GmbH				●		
Roche Austria GmbH		●				
Roche Diagnostics GmbH						●
Rockfish Bio AG	●					
ROKITAN GmbH						●
Rosta Biotech GmbH	●					
Roxall Medizin GmbH						●
S.MED Handels GmbH						●
SAICO Biosystems KG	●					
Sandoz Austria GmbH						●
SANOFI-AVENTIS GmbH		●				
Sanova Pharma GesmbH						●

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
Sartorius Stedim Austria GmbH				●		
Scan-Cargo Internationales Speditions-Service Gesellschaft m.b.H.					●	
Schwabe Austria GmbH			●			
Seagen Austria GmbH						●
Servier Austria GmbH			●			
Siemens AG Österreich					●	
Sigma Aldrich Handels GmbH.				●		
Sigmapharm Arzneimittel GmbH			●			
Sinapharm GmbH						●
SPLIPHARM Arzneiwaren HandelsgmbH						●
STADA Arzneimittel Gesellschaft m.b.H.						●
S-TARget therapeutics GmbH	●					
Stelopharm GmbH						●
Swedish Orphan Biovitrum GmbH						●
Syconium Lactic Acid GmbH	●					
SZABO-SCANDIC HandelsgmbH				●		
Takeda Manufacturing Austria AG		●				
Takeda Pharma GmbH						●
TAmiRNA GmbH	●					
Technoclone Herstellung von Diagnostika und Arzneimitteln Gesellschaft m.b.H.	●					
The Antibody Lab GmbH	●					
Thea Pharma GmbH						●
Thermo Fisher Diagnostics Austria GmbH						●
Thermo Fisher Scientific wissenschaftliche Geräte GmbH				●		
Thoeris GmbH	●					
THT BIOMATERIALS GmbH	●					

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
TissueGnostics GmbH		●				
Tridem Bioscience GmbH & Co KG	●					
Trigal Pharma GmbH			●			
Tube Pharmaceuticals GmbH	●					
UCB Pharma Gesellschaft m.b.H.		●				
UpNano GmbH		●				
Valneva Austria GmbH	●					
Vana Gesellschaft m.b.H.						●
VelaLabs GmbH	●					
VERDI Solutions GmbH	●					
Vertex Pharmaceuticals GmbH						●
Vetoquinol Österreich GmbH						●
Viatrix Austria GmbH						●
VIDIPHARM GmbH	●					
Vienna Biocenter Core Facilities GmbH					●	
ViennaLab Diagnostics GmbH	●					
Vifor Pharma Österreich AG						●
Viravaxx AG	●					
Virusure Forschung und Entwicklung GmbH					●	
Vita 34 Gesellschaft für Zelltransplantate m.b.H.	●					
Vivaldi Biosciences AG	●					
VOGELBUSCH Biocommodities GmbH				●		
VOGELBUSCH Biopharma GmbH				●		
VTL GmbH	●					
VWR International GmbH				●		
Wabosan Arzneimittelvertriebs GmbH						●
X4 Pharmaceuticals (Austria) GmbH	●					

	Dedicated biotech company	Biotech active company	Pharma company	Supplier	Service provider	Sales company
YASARA Biosciences GmbH	●					
YGION Biomedical GmbH	●					
ZAK-Pharma Dienstleistung Ges.m.b.H.					●	
Zoetis Österreich GmbH						●
Zytoprotec Flexible Kapitalgesellschaft	●					

Table 11: List of biotechnology and pharmaceutical companies in Vienna covered by the statistical analysis

Medical device companies in Vienna covered by the statistical analysis

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
“MEDOS GmbH“					●
123 Sonography GmbH	●				
1BillionLives GmbH	●				
3M Österreich GmbH					●
4myHealth GmbH	●				
A. Menarini GmbH					●
Abbott Medical Austria Ges.m.b.H					●
ACETO Medizinische Informationssysteme GmbH & Co KG	●				
Achim Schulz-Lauterbach Vertrieb medizinischer Produkte GmbH					●
Agilent Technologies Österreich GmbH					●
Akribes Biomedical GmbH	●				
ALBIS Plastic Vertriebsgesellschaft m.b.H.			●		
Alcon Ophthalmika GmbH	●				
ALLECTRIC GmbH AT	●				
Allergopharma Vertriebsges. mbH					●
ALSIX GmbH	●				
amacord GmbH					●
AME International GmbH				●	
Amex Healthcare GmbH					●
Amiola Medical Devices e.U.					●
appointmed GmbH				●	
ARCHIMEDlife GmbH		●			
Arjo Austria GmbH					●

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
Ascense Medical GmbH	●				
Ascensia Diabetes Care Austria GmbH					●
ASKIN & CO GmbH					●
Asprion Augenprothetik, Nikolaus Kerbl e.U.	●				
Assista Laborelectronics GmbH	●				
AURIMOD GmbH	●				
austro dent GmbH					●
AVVie GmbH	●				
Bauerfeind GmbH					●
Bausch & Lomb GmbH					●
Baxter Medical Products GmbH	●				
Beckman Coulter GmbH					●
Becton Dickinson Austria GmbH					●
Beiersdorf Gesellschaft m.b.H.					●
Bertmann Ges.m.b.H.			●		
BIMED Dr. Karner Spitalbedarfs GmbH					●
Bio-Klima-Institut Gesellschaft m.b.H.					●
biolitec AG					●
Biome Diagnostics GmbH	●				
Biomechanische Forschungs-Gesellschaft m.b.H. & Co KG				●	
BIOMEDICA Medizinprodukte GmbH	●				
bioMérieux Austria GmbH					●
Bio-Rad Laboratories Gesellschaft m.b.H.					●
Biotronik Vertriebs-GmbH					●
BIOVENDOR GesmbH					●
Bloom Diagnostics GmbH	●				

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
Bloomblisser GmbH				●	
BMS Informationstechnologie GmbH			●		
BOSCH + SOHN GMBH U. CO. KG - Zweigniederlassung Österreich					●
Boston Scientific GmbH					●
Braincon GmbH & Co KG	●				
Brainhero GmbH		●			
BrightComSol GmbH		●			
Brightmind.AI GmbH	●				
BSTÄNDIG VERBANDSTOFFFABRIK GmbH					●
CAATS Service GmbH	●				
cannmedic GmbH					●
Cardinal Health Austria 504 GmbH					●
CareTec International GmbH					●
Carl Reiner GmbH	●				
Carl Zeiss GmbH					●
CATALYST SCIENTIFIC GmbH				●	
Chateau Natal GmbH	●				
Chemische Fabrik Dr. Weigert Handelsgesellschaft m.b.H.			●		
Chemomedica Medizintechnik und Arzneimittel Vertriebsges.m.b.H.					●
Cherry Med Medical Solutions GmbH					●
CLIMED Medizinische Produkte Produktions- und Vertriebs-GmbH					●
Clinical Standard GmbH					●
CogVis Software und Consulting GmbH			●		
Coloplast Ges.m.b.H					●
CompuGroup Medical CEE GmbH				●	
Compumedics - alpha trace GmbH	●				

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
contextflow GmbH	●				
ConvaTec (Austria) GmbH					●
Cook Österreich GmbH					●
Cordis Medical GmbH					●
Corin GSA GmbH, Niederlassung Austria					●
Creative Medical GmbH	●				
Crosstec GmbH					●
Cubicure GmbH			●		
CVTec Cerebrovascular Technologies GmbH	●				
D.A.T.A. Corporation Softwareentwicklungs GmbH	●				
Dahlhausen GmbH					●
Dedalus HealthCare Ges.m.b.H.	●				
Dedicaid GmbH	●				
Dentsply Sirona Austria GmbH					●
Derma Medical Systems Handels- und Entwicklungs GmbH	●				
DEXCOM INTERNATIONAL LIMITED - Zweigniederlassung Österreich					●
DEZIMAL GmbH	●				
Dia-Chrom Handelsgesellschaft m.b.H.					●
DiaSorin Austria GmbH					●
Disinfect Plus GmbH				●	
Dr. A. & L. Schmidgall GmbH & Co KG					●
Dr. Schuhfried Medizintechnik GmbH	●				
Dräger Austria GmbH					●
Edwards Lifesciences Austria GmbH					●
Ekomed Handels-Ges.m.b.H					●
embecta Austria GmbH					●

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
EMTensor GmbH	●				
en.co.tec Schmid KG				●	
epitome GmbH	●				
Eppendorf Austria GmbH			●		
Erbe Elektromedizin Ges.m.b.H.					●
Ernst Wittner Gesellschaft m.b.H.			●		
EUBIO, ANDREAS KÖCK e.U.					●
Eumedics Medizintechnik Handels- und Marketingges.m.b.H.					●
Ewald Baumgartner Feinoptik Gesellschaft m.b.H.			●		
Exactech EÖG GmbH				●	
Exeltis Austria GmbH					●
Exomys-Augmented Humanity GmbH		●			
F. Schmidl & Co GmbH	●				
FemPulse GmbH	●				
Ferdinand Menzl Medizintechnik GmbH					●
Fidia Pharma Austria GmbH					●
Fisher & Paykel Healthcare GmbH - Zweigniederlassung Österreich					●
Fresenius Medical Care Austria GmbH					●
FUJIFILM Austria GmbH					●
GE Healthcare Handels GmbH					●
Gepa-Med Medizintechnik GmbH					●
Gerhard Pejcl Medizintechnik Handels GmbH					●
GETINGE Österreich GmbH		●			
GN Hearing Austria GmbH					●
Gynial GmbH					●
Haemonetics Handelsgesellschaft mbH					●

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
HappyMed GmbH	●				
HARPS Europe GmbH					●
HARPS Europe Manufacturing GmbH		●			
Health Force GmbH	●				
HearO GmbH	●				
heartfish GmbH	●				
Helga Health GmbH	●				
Hellmut Habel Gesellschaft m.b.H.					●
Henry Schein Dental Austria GmbH					●
Henry Schein Medical Austria GmbH					●
hi.health GmbH	●				
HOLLISTER GmbH					●
Hologic Austria GmbH					●
HO-MED Handelsgesellschaft m.b.H.					●
HöR-AKUSTiK DöBLING GmbH		●			
Hospitec Warenhandels-gesellschaft m.b.H.					●
IB Lab GmbH	●				
IDEXX Vet Med Labor GmbH					●
Impairment Analytics DH2S GmbH	●				
Ing. Fritz Kern Gesellschaft m.b.H.			●		
Ing. Sumetzberger GmbH			●		
Innovative Diagnostics Vertriebsges.m.b.H.					●
Insulet Austria GmbH					●
INTRAMED Handels Ges.m.b.H.					●
Intuitive Surgical Österreich GmbH					●
Ivoclar Vivadent GmbH					●

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
JEDER GmbH	●				
Johnson & Johnson Medical Products GmbH					●
Karl Rejlek GmbH			●		
Karl Storz Endoskop Austria GmbH					●
KCI Austria GmbH					●
Krainer Medtechnik Handelsgesellschaft mbH					●
Kulzer Austria GmbH					●
Kybermed Handelsgesellschaft mbH					●
Lab Technologies Medizintechnik GmbH					●
Laser-Gruppe-Materialbearbeitungs GesmbH			●		
LB-systems GmbH					●
LeadMe HSW GmbH	●				
LifeScan Österreich GmbH					●
Lima Austria GmbH					●
Lithoz GmbH			●		
LivaNova Austria GmbH					●
LKB Vertriebs-Gesellschaft m.b.H.					●
Luna-IP GmbH		●			
M+W Dental Handels GmbH					●
MacroArray Diagnostics GmbH	●				
Masimo Österreich GmbH					●
Mavie Next GmbH				●	
MCW Handelsgesellschaft m.b.H.				●	
mdc medical device certification GmbH - Zweigniederlassung Österreich				●	
MED Technologies GmbH					●
Medbee GmbH	●				

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
Medcem GmbH					●
MedCom Medizinische Softwareerstellungs- und VertriebsgmbH				●	
Medexter Healthcare GmbH	●				
Medichron Institut für Diagnostik und Therapie chronischer Erkrankungen Gesellschaft m.b.H.					●
Medicus AI GmbH	●				
Medifina Medizinprodukte Vertriebs-GmbH	●				
Medivs Pharma GmbH					●
Medix GmbH					●
med-lab GmbH					●
Medline Austria GmbH					●
medmobile GmbH					●
Medtronic Österreich GmbH					●
Michael Hauser Medizintechnik					●
MicroPort CRM Austria GmbH					●
MiiCare Austria GmbH					●
MIN Medical Innovation Network GmbH					●
Mölnlycke Health Care GmbH					●
MorphoMed GmbH	●				
MR Medical Handels GmbH					●
MSP Medizintechnik GmbH					●
MTG - Medizinisch Technische Geräte Erzeugungs- und Vertriebsgesellschaft mbH					●
Multisana medizinisch-technische Geräte Handelsgesellschaft m.b.H.					●
myResQ GmbH	●				
mySugr GmbH	●				

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
Nestle Österreich GmbH					●
NEURODATA Handels-GmbH					●
NewMedX Medizinprodukte Vertriebs und Consulting GmbH					●
Nobel Biocare (Österreich) GmbH					●
Novid20 GmbH				●	
Novomed Handelsgesellschaft mbH					●
nyra health GmbH	●				
Olympus Austria GmbH					●
ONDEWO GmbH				●	
Ordibed GmbH					●
OrphaCare GmbH	●				
ORTHOMED Medizintechnik GmbH					●
Orthorobot Medizintechnik GmbH	●				
Otto Bock Healthcare Products GmbH	●				
OXYCARE Medizintechnik GmbH					●
P+F Cardiovascular GmbH	●				
P+F Products + Features GmbH	●				
PH Palden GmbH					●
Pharma Consult Ges.m.b.H.	●				
Philips Austria GmbH					●
Photonic Optische Geräte Gesellschaft m.b.H. & Co. KG		●			
piur imaging GmbH	●				
PKP Handelsges.m.b.H.					●
Plandent GmbH					●
Plasmics GmbH			●		
Pohlig Austria GmbH & Co KG	●				

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
Polytech Domilens GmbH - Zweigniederlassung Österreich					●
Posthorax GmbH					●
psimistri GmbH	●				
Remesco HandelsgesmbH					●
REPULS Lichtmedizintechnik GmbH	●				
REPULS PDI GmbH	●				
RetInSight GmbH			●		
Richard Wolf Austria GmbH					●
Roche Diabetes Care Austria GmbH					●
room4 Softwareentwicklung GmbH	●				
Roots Health GmbH	●				
Rosner GmbH - Medizintechnik					●
rotable technologies GmbH			●		
Rudolf Heintel Gesellschaft m.b.H.					●
Rüsch Austria Gesellschaft mbH					●
Sakura Finetek Austria GmbH					●
SALESIANER MIETTEX GmbH				●	
SANAG HEALTHCARE GmbH					●
SCARLETRED Holding GmbH	●				
Schülke & Mayr GmbH			●		
Semadeni Ges.m.b.H.			●		
SER Solutions Österreich GmbH			●		
SIC invent Austria GmbH					●
SICO Pharma GmbH					●
Siemens Healthcare Diagnostics GmbH					●
Sigvaris, medizinische Kompressionsstrümpfe Gesellschaft mbH					●

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
SIMCharacters GmbH				●	
SIMStation GmbH	●				
SNORE FREE GmbH	●				
Soma Reality GmbH			●		
speak23 GmbH				●	
Spine-Med Ges.m.b.H.					●
Stago Österreich GmbH					●
Stefan Limbeck, Alleininhaber Richard Limbeck e.U.					●
Stemcup Medical Products Austria GmbH					●
STINA Medical Solutions GmbH			●		
Stryker Austria GmbH					●
SUN MED Medizintechnische Produkte GmbH					●
Symptoma GmbH	●				
Sysmex Austria GmbH					●
tec4life Medizintechnik GmbH					●
TETRAGON Braille Systems GmbH	●				
The Ceutics Company GesmbH					●
The Siesta Group Schlafanalyse GmbH				●	
THP Medical Products Vertriebs-GmbH					●
TiliaHealth FlexCo	●				
TRAUMA CARE CONSULT Traumatologische Forschung Gemeinnützige Gesellschaft mbH				●	
Treetop Medical GmbH	●				
TRIBUS medical Handels GmbH					●
Trignostics GmbH					●
TWO PI Signal Processing Applications GmbH			●		

	Dedicated medical device company	Company active in medical devices	Supplier	Service provider	Sales company
TZMO Austria GmbH					●
Valeriot GmbH	●				
VAMED Standortentwicklung und Engineering GmbH				●	
VAMED-KMB Krankenhausmanagement und Betriebsführungsges.m.b.H.				●	
VISTA MEDICAL Medizintechnik GmbH					●
VISUAPPS GmbH				●	
VitreabLab GmbH		●			
VIVISOL Heimbehandlungsgeräte GmbH	●				
Wagner & Munz GmbH					●
Waters Gesellschaft m.b.H.			●		
Wavesense Engineering GmbH	●				
Websinger GmbH	●				
Wellspect HealthCare GmbH					●
Werfen GmbH					●
XUND Solutions GmbH				●	
Zimmer Biomet Austria GmbH					●
Zoll Medical Österreich GmbH					●

Table 12: List of medical device companies in Vienna covered by the statistical analysis

Research and education organisations in Vienna covered by the statistical analysis

	Non-university research organisation	University of applied sciences	University
AIT Austrian Institute of Technology GmbH	●		
Austrian Breast & Colorectal Cancer Study Group (ABCSCG)	●		
Gregor Mendel Institute of Molecular Plant Biology (GMI)	●		
Institute of Molecular Biotechnology (IMBA)	●		
Ludwig Boltzmann Gesellschaft (LBG)	●		
Max Perutz Labs	●		
Medical University of Vienna			●
Österreichisches Forschungsinstitut für Chemie und Technik (OFI)	●		
Research Center for Molecular Medicine (CeMM)	●		
Research Institute of Molecular Pathology (IMP)	●		
Sigmund Freud Private University Vienna (SFU)			●
St. Anna Children's Cancer Research Institute (CCRI)	●		
TU Wien			●
University of Applied Sciences FH Campus Wien		●	
University of Applied Sciences Technikum Wien		●	
University of Natural Resources and Life Sciences, Vienna (BOKU University)			●
University of Veterinary Medicine, Vienna (Vetmeduni)			●
University of Vienna			●
VRVis Zentrum für Virtual Reality und Visualisierung Forschungs-GmbH	●		

Table 13: Research and education organisations in Vienna covered by the statistical analysis

Other organisations in Vienna covered by the statistical analysis

	Governmental entities	Special interest groups	Funding and support agencies	Start-up service providers	Additional organisation
AAL Austria - Innovationsplattform für intelligente Assistenz im Alltag		●			
AGES - Austrian Agency for Health and Food Safety GmbH	●				
Association of the Austrian Chemical Industry - FCIO		●			
Austria Wirtschaftsservice GmbH (aws)			●		
Austrian Academy of Sciences (ÖAW)					●
Austrian Association of Molecular Life Sciences and Biotechnology (ÖGMBT)		●			
Austrian BioImaging Association/CMI		●			
Austrian Biotech Industry (ABI)		●			
Austrian Business Agency (ABA)			●		
Austrian Council for Sciences, Technology and Innovation (FORWIT)	●				
Austrian Economic Chambers (WKO)		●			
Austrian Medicines Verification Organisation - AMVO		●			
Austrian Research Promotion Agency (FFG)			●		
Austrian Science Fund (FWF)			●		
Austrian Society for Allergy and Immunology (ÖGAI)		●			
Austrian Society of Dermatology and Venereology (ÖGDV)		●			
Austrian Society of Pneumology (ASP)		●			
Austrian Society of Tropical Medicine, Parasitology and Migration Medicine (ASTPM)		●			
Austrian Standards International - Standardisierung und Innovation	●				
AUSTROMED - Association of Medical Devices Manufacturers in Austria		●			
Association for the Promotion of Artificial Intelligence in Austria (AI Austria)		●			
BAES - Austrian Federal Office for Food Safety	●				
BASG - Austrian Federal Office for Safety in Health Care	●				

	Governmental entities	Special interest groups	Funding and support agencies	Start-up service providers	Additional organisation
BAVG - Austrian Federal Office for Consumer Health	●				
Bioeconomy Austria Ökosoziales Forum Österreich & Europa		●			
BIOS Science Austria		●			
Biosimilarsverband Österreich		●			
BIOTECH AUSTRIA - Association of the Biotechnology Industry in Austria					
Bundesamt für Eich- und Vermessungswesen (BEV)	●				
Bundesanstalt für Agrarwirtschaft und Bergbauernfragen	●				
BTA - BioTech Association		●			
Central European Cooperative Oncology Group (CECOG)		●			●
Christian Doppler Forschungsgesellschaft (CDG)			●		
College of Physicians in Vienna (GDAE)		●			
Complexity Science Hub Vienna (CSH)					●
Verein DEXHELPP zur Forschungsförderung im Gesundheitssystem					●
EANM Forschungs GmbH European Association of Nuclear Medicine		●			
EIT Health Austria GmbH				●	
ELGA GmbH	●				
European Institute for Biomedical Imaging Research (EIBIR)					●
European Society of Radiology (ESR)		●			
FEEI – Fachverband der Elektro- und Elektronikindustrie		●			
Forum der forschenden pharmazeutischen Industrie (FOPI)		●			
Fraunhofer Austria Research GmbH					●
FUTURE HEALTH LAB GmbH					●
Gesellschaft für Pharmazeutische Medizin (GPmed)		●			
Gesundheit Österreich GmbH	●				
Haus des Meeres – Aqua Terra Zoo GmbH					●
Health Hub Vienna				●	
Health Pioneers - Verband digitale Gesundheitsversorgung Österreich		●			

	Governmental entities	Special interest groups	Funding and support agencies	Start-up service providers	Additional organisation
Hochschule für Agrar- und Umweltpädagogik Wien	●				
HTA Austria - Austrian Institute for Health Technology Assessment GmbH (AIHTA)					●
ICC - International Association for Cereal Science		●			
IHE Austria - Verein zur Förderung der Integration der IT- und Medizintechnik in das österreichische Gesundheitswesen		●			
INiTS Universitäres Gründerservice Wien GmbH				●	
Johanniter Österreich Ausbildung und Forschung gemeinnützige GmbH					●
Johanniter-Unfall-Hilfe in Österreich					●
LISAvienna – Life Science Austria Vienna				●	
Natural History Museum Vienna (NHM)					●
Open Science		●			
Österreichische Chemische Gesellschaft (GÖCH)		●			
Österreichische Gesellschaft für Chirurgie (ÖGCH)		●			
Österreichische Gesellschaft für Ernährung - ÖGE Austrian Nutrition Society - ANS		●			
Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH)		●			
Österreichische Gesellschaft für Hals-, Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie		●			
Österreichische Gesellschaft für Laboratoriumsmedizin und Klinische Chemie (ÖGLMKC)		●			
Österreichische Gesellschaft für Neurologie (ÖGN)		●			
Österreichische Gesellschaft für Nuklearmedizin und Thera­nostik (OGNT)		●			
Österreichische Gesellschaft für Orthopädie und orthopädische Chirurgie		●			
Österreichische Gesellschaft für Qualitätssicherung und Standardisierung Medizinisch-diagnostischer Untersuchungen (ÖQUASTA)		●			

	Governmental entities	Special interest groups	Funding and support agencies	Start-up service providers	Additional organisation
Österreichische Gesellschaft für Radioonkologie, Radiobiologie und Medizinische Radiophysik (ÖGRO)		●			
Österreichische Gesellschaft für Urologie und Andrologie (ÖGU)		●			
Österreichische Röntgengesellschaft, Gesellschaft für Medizinische Radiologie und Nuklearmedizin		●			
Österreichischer Generikaverband		●			
Österreichischer Pharma Cercle (ÖPHC)		●			
Österreichischer Verband der Impfstoffhersteller (ÖVIH)		●			
Österreichisches Patentamt	●				
Pharma Marketing Club Austria (PMCA)		●			
PHARMIG – Association of the Austrian Pharmaceutical Industry		●			
Schönbrunner Tiergarten-Gesellschaft m.b.H.					●
The Austrian Self Care Association (IGEPHA)		●			
Umweltbundesamt (UBA) - Environment Agency Austria	●				
Verband der Österreichischen Arzneimittelvollgroßhändler PHAGO		●			
Verein Österreichischer Lebensmittel- und Biotechnologen (VÖLB)		●			
Vienna BioCenter		●			
Vienna Business Agency			●		
Vienna Open Lab					●
Vienna Science and Technology Fund (WWTF)			●		
wings4innovation GmbH					●

Table 14: List of other organisations in Vienna covered by the statistical analysis

Equity investments and other major capital infusions

Date	Company	Details	€ million
Total disclosed investment volume 2021-2024 (excluding transactions for which no specific financial details have been communicated excluding agreements not disclosed to the public)			1,676.7
Total disclosed investment volume 2021			293.8
Q1/2021	a:head bio	7-digit financing round	
	allcyte	Seed investment round (\$6m)	5.1
	Evologic Technologies	Financing round (€2.5m)	2.5
	Hello Inside Roots Health	7-digit financing round with business angels	
	Nabriva	Direct offering (\$25.4m)	21.1
	X4 Pharmaceuticals	Private investment in public equity financing (\$55m)	46
Q2/2021	BioCraft Pet Nutrition	Seed investment round (n.d.)	
	Cutanos	First financing round (n.d.)	
	Delta4ai	Multi-million series A financing round	
	HeartBeat.bio	Seed financing (€1.5m)	1.5
	JLP Health	Private equity investment (€12m)	12
	Lithoz	INKplant EU project with 19 partners (total volume: €6m company share: n.d.)	
	Revo Foods	Seed investment round (€1.5m)	1.5
	Valneva	Global offering (\$107.6m)	89.6
	XUND	Angel investment (€1m)	1
Q3/2021	contextflow	Series A investment round (€6.7m)	6.7
	Platomics	Series A investment round (€14m)	14
Q4/2021	F4 Pharma	COVend EU project with 17 partners (total volume: ~€10m company share: €2.6m)	2.6
	incus	Series A investment round (n.d.)	
	nyra health myReha	Pre-seed investment round (€2.2m)	2.2
	Rockfish Bio	Seed investment round (n.d.)	
	Valneva	Global offering (\$102m)	88

Date	Company	Details	€ million
Total disclosed investment volume 2022			552.6
Q1/2022	Cellectric Biosciences	Pre-seed round (€0.5m)	0.5
	HOOKIPA Pharma	Public offering (\$75m)	67.4
	Profem	Conda crowdfunding (€1m)	1
	Ribbon Biolabs	Series A investment round (€18m)	18
	rotatable	6-digit pre-seed financing round	
	Valneva	Scottish Enterprise grant (£20m)	24
Q2/2022	AVVie	EIC Grant (€2.5m)	2.5
	Fermify	Pre-seed investment round (n.d.)	
	piur imaging	Series A investment round (€2m)	2
	Valneva	Equity investment by Pfizer (\$95m)	90.5
	Valneva	Deerfield Management Company and OrbiMed: Loan (\$40m)	37.6
Q3/2022	X4 Pharmaceuticals	Private placement financing and debt facility amendment (\$55m)	52.5
	Brightmind.AI	Public funding and private investment (n.d.)	
	F2G Ltd.	Private equity investment (\$70m)	68.3
	LIVIN farms	Series A investment round (\$5.8m)	6
	UpNano	Equity investment by existing investors (n.d.)	
Q4/2022	Revo Foods	EU grant for LIKE-A-PRO project (€13.9m / €0.8m)	0.8
	XUND	Seed investment round (€6m)	6
	AOP Health	Loan granted to Shield Therapeutics plc (\$10m)	9.4
	Flinn.ai	Pre-seed investment round (€1.8m)	1.8
	Valneva	Global offering (€102.9m)	102.9
	X4 Pharmaceuticals	Public Offering (\$65m)	61.4
Total disclosed investment volume 2023			374.3
Q1/2023	dawn-bio	Pre-seed investment; new subsidiary in Copenhagen was granted a convertible loan (n.d.)	
	hi.health	Pre-Series A investement round (€6m)	6
	HOOKIPA Pharma	Milestone payment from Gilead Sciences (\$5m)	4.7

Date	Company	Details	€ million
	HOOKIPA Pharma	Milestone payment from Roche (\$10m)	9.3
	Revo Foods	Joint EU grant with Mycorena (total volume: €1.5m company share: n.d.)	
Q2/2023	Cellectric Biosciences	Pre-seed extension round (€0.5m)	0.5
	Fermify	Seed investment round (\$5m)	4.5
	HOOKIPA Pharma	Public offering (\$50m)	46.8
	nyra health	Seed investment round (€4.5m)	4.5
	Vivaldi Biosciences	EU grant (total volume: €7.6m company share: n.d.)	
	X4 Pharmaceuticals	Private Placement (\$65m)	59.8
Q3/2023	contextflow	EIC Accelerator Equity Investment (€7.5m)	7.5
	Fermify	Extension of seed investment round (€1.5m)	1.5
	piur imaging	Series A financing round (€4.9m)	4.9
	Valneva	Deerfield Management Company and OrbiMed: Loan (\$100m)	92
	X4 Pharmaceuticals	Loan from Hercules Capital (\$115m)	105
Q4/2023	BrightComSol	First private investment (n.d.)	
	HeartBeat.bio	Pre-Series A financing round (€4.5m)	4.5
	HOOKIPA Pharma	Equity investment (\$21.25m)	19.3
	nagene	Private equity (€1m)	1
	Vivaldi Biosciences	Grant from Flu Lab (n.d.)	
	Zytotec	Equity investment (€2.5m)	2.5
Total disclosed investment volume 2024			456.0
Q1/2024	Cellectric Biosciences	Eurostars project (total volume: €2.7m grant company share: n.d.)	
	G.ST Antivirals	Series A investment round (€6.2m)	6.2
	RetInSight	EU grant for I-SCREEN project (total volume: €4.7m company share: n.d.)	
	QUANTRO Therapeutics	Seed investment extension (convertible)	
	Valneva	Sale of Priority Review Voucher (\$103m)	95
Q2/2024	HOOKIPA Pharma	Million milestone payment from Roche (\$10m)	9.3
	imd BIOTECH	Angel investment (€0.4m)	0.4
	Somareality Is	Investment round (€1.5m)	1.5

Date	Company	Details	€ million
	X4 Pharmaceutica	Sale of Priority Review Voucher (\$105m)	97.4
	XUND	Investment by Thieme Group (€2m)	2
	YGION Biomedical	Series A investment round (€15m)	15
Q3/2024	F2G Ltd.	Financing round (\$100m)	90.3
	Flinn.ai	Seed investment round (€6m)	6
	Hello Inside Roots Health	Seed investment (€1.65m)	1.65
	HOOKIPA Pharma	Milestone payment from Gilead (\$5m)	4.6
	invIOs	Investment by Ligand linked to acquisition of APEIRON Biologics (\$4m)	3.7
	Revo Foods	EU project in collaboration with Paleo granted (€2.2m)	0.8
	Revo Foods	FunderNation Crowdfunding (1.2m)	1.2
	Valneva	Equity raise (€61.2m)	61.2
	Valneva	Grant from CEPI / EU (\$41.3m)	37.9
Q4/2024	a:head bio	€7-digit pre-Series A funding (n.d.)	
	aitiologic	€2.5 million in total funding to date, including non-dilutive grants from aws and FFG	2.5
	invIOs	Series A investment round (€8.2m)	8.2
	Rockfish Bio	Capital increase and FFG grant (€1.5m)	1.5
	Somareality	Seed investment (€2.6m)	2.6
	UpNano	Series A investment round (€7m)	7

Table 15: List of equity investments and other major capital infusions

(This list is not exhaustive and focuses on announced transactions. It does not indicate whether and when funds were actually disbursed unless indicated otherwise. Several companies operate multiple sites across the globe. Press releases only occasionally allow the role of regional branches to be identified, or the impact of transactions on them to be determined. Therefore, not every listed case directly impacts the Vienna branch. Dollar amounts were converted using the exchange rate applicable at the time of the respective press release, unless also stated in euros therein. n.d.: Financial volume of transaction not disclosed)

Licensing, M&A activities, site expansions and additional agreements

Date	Company	Details	€ million
Sum of disclosed deal volumes 2021-2024 (excluding decisions for which no specific financial details have been communicated excluding agreements not disclosed to the public)			6,058.8
Total disclosed deal volume 2021			953.9
Q1/2021	a:head bio	Collaboration with 3Brain on high-density, high-throughput MEA systems	
	AOP Health	Partnership with Tuteur to bring treatment to patients suffering from Pulmonary Arterial Hypertension in Argentina	
	Cebina	Partnership with URSAPHARM Arzneimittel to repurpose the antihistamine azelastine to combat COVID-19	
	Lithoz	Strategic collaboration with Metoxit and Dr. Jens Tartsch on ceramic dental implants via additive manufacturing	
	F4 Pharma	Licensing and collaboration agreement with SIRS Therapeutics and Therapeutics PTx	
Q2/2021	allcyte	Acquisition by Exscientia (€50m)	
	Biomay	Cooperation with BioNTech to supply DNA template for COVID-19 mRNA vaccine	
	Boehringer Ingelheim	Cooperation with Lifebit Biotech and opening of a competence center for poultry vaccination	
	Cebina	Launch of Danube Labs together with Evotec	
	Evercyte	Partnership with MDimune for developing tumor- targeting EVs	
	Myllia Aelian Biotechnology	Collaboration agreement with GSK to apply single-cell CRISPR screening for drug target discovery	
	XUND	Collaboration with Thieme	
Q3/2021	AFFiRiS	AC Immune acquisition of immunotherapy anti-alpha-synuclein programs targeting neurodegenerative diseases (\$63.7m €53.9m)	
	AOP Health	Licensing agreement with Eagle Pharmaceuticals targeting the U.S. market	
	contextflow	Partnership with Wellbeing Software to deliver dynamic AI clinical decision support to radiologists	
	HOOKIPA Pharma	Clinical collaboration and supply agreement with Merck & Co., Inc. (MSD)	

Date	Company	Details	€ million
Q4/2021	Lexogen	Strategic partnership with Scaillyte to create a joint biomarker discovery workflow for precision medicine companies	
	Nabriva	Agreement with Vizient targeting more than half of U.S. hospitals	
	Thoeris	Partnership with Boehringer Ingelheim	
	XUND	Partnership with Wiener Städtische	
	AFFiRiS	Frontier Biotechnologies obtains exclusive rights in Greater China	
	Boehringer Ingelheim	Opening of a new biopharmaceutical production facility in Vienna (€700m)	
	contextflow	Technology integration collaboration with Dedalus HealthCare	
	ImageBiopsy Lab	Collaboration with OXOS Medical Partnership with Human Bytes In-licensing of UCB AI technology	
	Origimm	Acquisition by Sanofi	
	PhagoMed	Acquisition by BioNTech (€150m)	
Q1/2022	Valneva	Advance purchase agreement for inactivated COVID-19 vaccine with the European Commission	
	Virusure	Asahi Kasei Life Science acquired Bionique Testing Laboratories: Virusure and Bionique join forces in providing biosafety testing services	
	XUND	Partnership with Generali Health Solutions	
	Total disclosed deal volume 2022		2,009.6
Q1/2022	contextflow	Distribution partnership with Alma Medical	
	Herba Chemosan Group	Management Buy-Out	
	HOOKIPA Pharma	Amendment of collaboration and license agreement with Gilead to develop immunotherapies against HIV (\$50m €44m)	
	Lexogen	Partnership with Singular Genomics to enable RNA library prep for the G4 sequencing platform	
	MacroArray Diagnostics	Distribution partnership with ALPCO to serve the North American market	
	piur imaging	Partnership with Fujifilm VisualSonics	
Q2/2022	contextflow	Partnership with Elsevier's STATdx platform Partnership with Alphasat Medical	
	Delta4ai	Collaboration agreement with 4P-Pharma on treatments for a rare autoimmune chronic liver disease	
	F2G Ltd.	Strategic collaboration with Shionogi to develop and commercialize an antifungal agent in Europe and Asia (\$480m €459.9m)	

Date	Company	Details	€ million
Q3/2022	Proxygen	Strategic collaboration with Merck KGaA on molecular glue degraders for clinical research (\$554m €495m)	
	Nabriva	Extension of distribution agreement with Merck (MSD) focusing on the U.S.	
	AOP Health	Drug development agreement with Leukos Biotech Launch of new packaging facility in Vienna	
	Boehringer Ingelheim	Groundbreaking ceremony: New cancer research facility in Vienna (€60m)	
	contextflow	Partnership with RevealDx Partnership with Oxipit	
	Eucodis Bioscience	Acquisition by Biosynth Carbosynth	
	HeartBeat.bio	Co-development agreement with Molecular Devices on cardiac organoids for high-throughput screening	
	Medbee	Acquisition by Springer Nature Health	
	Nabriva	Exclusive distribution agreement for several countries with Er-Kim Pharmaceuticals	
	QUANTRO Therapeutics	Collaboration with Boehringer Ingelheim (upfront payment)	
Q4/2022	contextflow	Partnership with Softway Medical Group	
	Evologic Technologies	Partnership with Calyxt on ingredients for cosmeceutical, nutraceutical and pharmaceutical markets	
	HeartBeat.bio	Collaboration with Boehringer Ingelheim on human cardiac organoids for drug discovery	
	HOOKIPA Pharma	Strategic collaboration and license agreement with Roche (\$930m €950.7m)	
	Lithoz	Acquisition of CerAMing	
Total disclosed deal volume 2023			2,696.9
Q1/2023	contextflow	Partnership with Medexprim Partnership with Collective Minds Radiology	
	Lithoz	360° partnership with ZENIT Smart Polycrystals Sales partnership with Wendt India	
	TAmiRNA	Partnership with Biogenity to enable multi-omics workflows combining proteomics and transcriptomics	
Q2/2023	BiomeDx	Strategic partnership with SanusX	
	ingenetix	Near tripling of operating space in Vienna	
	Lithoz	Innovation partnership with Glassomer Strategic partnership with SiNAPTIC	
	Proxygen	Collaboration and license agreement with Merck (MSD) on molecular glue degraders (\$2.55bn €2.34bn)	
	Ribbon Biolabs	Opening of new facilities in Vienna	
	Takeda	Opening of new Global Pathogen Safety Lab in Vienna	

Date	Company	Details	€ million
	ViennaLab Diagnostics	Partnership with Euformatics and Oncompass Medicine to win contract for liquid biopsy NGS solution	
Q3/2023	Cebina	Strategic collaboration with Charles River to accelerate neuroscience research into innovative therapeutics in the DanubeNeuro program	
	ImageBiopsy Lab	Collaboration agreement with Radiobotics Partnership with ConcertAI's TeraRecon	
	Lithoz	Partnership with Himed to drive 3D-printable medical-grade bioceramics Acquisition of a share in AMAREA Technology GmbH	
	Nabriva	Acquisition of key assets for several countries in Asia by Sumitomo Pharma (\$15m €13.6m)	
	Octapharma	Celebrating €200m expansion of Vienna production site realized over the last five years and breaking ground on a new €33m visual inspection, packaging and logistics facility	
	Sempermed	Acquisition by HARPS Global (€115m)	
	Takeda	Groundbreaking ceremony for a new „lab of the future“ in Vienna (€3-digit million investment)	
	Valneva	Supply contract with U.S. government (\$32m €30.2m)	
Q4/2023	Biomay	Expansion of GMP-facilities to offer mRNA manufacturing and aseptic filling services	
	contextflow	Partnership with Blackford (part of Bayer group of companies)	
	MacroArray Diagnostics	Austria's pioneer in allergy diagnostics expands	
	Lithoz	Cooperative R&D agreement with Oak Ridge National Laboratory	
	nyra health	Partnership with VAMED in Germany	
	piur imaging	Strategic partnership with Curium to advance thyroid diagnostics in Germany	
Total disclosed deal volume 2024			398.4
Q1/2024	bespark*bio	Strategic Alliance with Novasign	
	Cubicure	Acquisition by Align Technology (€79m)	
	HOOKIPA Pharma	Termination of agreement on HB-700 program in KRAS mutated cancers with Roche	
	Lexogen	Partnership with MGI focusing in the field of advanced RNA sequencing	
	MacroArray Diagnostics	Distribution partnership with Test4 Limited with focus on food intolerance testing	
	piur imaging	Collaboration with GE HealthCare to advance innovation with 3D thyroid ultrasound imaging	

Date	Company	Details	€ million
	QUANTRO Therapeutics	Collaboration with Boehringer Ingelheim (first milestone payment)	
	SIMCharacters	Exclusive worldwide distribution partnership with Laerdal	
	TAmiRNA	Exclusive distribution agreement for the Nordics with Techtum Labs	
Q2/2024	breathe ilo	Acquisition of assets by MAM after insolvency in 2023	
	cogvis	Tender in Sweden's model region Skåne won (n.d.)	
	contextflow	Partnership with Neologica	
	Evercyte	Collaboration with TAmiRNA and Phoenestra on extracellular vesicles (n.d.)	
	Lithoz	Launch of joint Bioceramics Center of Excellence™ (BCoE) with Himed	
	Rebel Meat	Acquisition of key assets by concept cool	
	Sempermed	Acquisition of remaining production and packaging of surgical gloves by HARPS Global (€7m)	
	Sigmapharm	Strategic collaboration with Rohto Pharmaceutical and acquisition (€30m)	
	TAmiRNA	Extended collaboration with Lepton Pharmaceuticals on microRNA immune therapy discovery	
	VAMED	Announcement of acquisition of majority of post-acute business by PAI Partners	
	VAMED	Announcement of planned acquisition of business segment focusing on Austria by Porr and Strabag (€90m)	
	Virusure	Collaboration with neotem Bioanalytics (n.d.)	
Q3/2024	APEIRON Biologics	Acquisition by Ligand Pharmaceuticals (\$100m €92.4m)	
	Biomay	Strategic partnership with Areterna to jointly serve mRNA CDMO customers in Europe and North America	
	Boehringer Ingelheim	Decision to construct a new office building at the company's campus in Vienna (€100m)	
	MacroArray Diagnostics	Partnership with labors.at	
	Nabriva	Acquisition of certain key assets for North America by Meitheal	
	Platomics	Partnerships with Illumina, Hamilton, Saphetor, SeqOne	
	RetInSight	Comprehensive collaboration with veonet to improve AMD care in several countries	
	Valneva	Strategic partnership with LimmaTech: Licensing deal for Shigella vaccine candidate	

Date	Company	Details	€ million
Q4/2024	contextflow	Collaboration agreement with Bayer Calantic	
	Evercyte	Partnership with AIM Biotech for microfluidic immortalized cell lines	
	Valneva	Exclusive license agreement with Serum Institute of India that enables supply of chikungunya vaccine in Asia	

Table 16: List of licensing, M&A activities, site expansions and additional agreements
 (This list is not exhaustive and focuses on announced transactions. It does not indicate whether and when funds were actually disbursed unless indicated otherwise. Several companies operate multiple sites across the globe. Press releases only occasionally allow the role of regional branches to be identified, or the impact of transactions on them to be determined. Therefore, not every listed case directly impacts the Vienna branch. Dollar amounts were converted using the exchange rate applicable at the time of the respective press release, unless also stated in euros therein.)

Focus of innovative medical device companies in Vienna

This list is not exhaustive. NEW: Founded in 2021, 2022 or 2023 NEW*: Founded in 2024	Active implantable devices	Anesthetic and respiratory devices	Assistive products for persons with disability	Biological-derived devices	Dental devices	Diagnostic and therapeutic radiation devices	Electromechanical medical devices	Hospital hardware	In-vitro diagnostic devices	Non-active implantable devices	Ophthalmic and optical devices	Reusable devices	Single-use devices	Software for medicine, telemedicine and e-health	Other products for healthcare	Additive manufacturing
123 Sonography GmbH														●		
NEW: 1BillionLives GmbH Flinn.ai														●		
4myHealth GmbH Latido Health Tech														●		
ACETO Medizinische Informationssysteme GmbH & Co KG														●		
Alcon Ophthalmika GmbH											●					
NEW: ALLECTRIC GmbH AT															●	
ALSIX GmbH								●								
appointmed GmbH														●		
ARCHIMEDlife GmbH									●							
NEW: Ascense Medical GmbH										●						
Asprion Augenprothetik, Nikolaus Kerbl e.U.											●					
Assista Laborelectronics GmbH														●		
AURIMOD GmbH							●							●		
AVVie GmbH	●									●						
Baxter Medical Products GmbH				●								●	●			
Biome Diagnostics GmbH									●							
BIOMEDICA Medizinprodukte GmbH AddLife Group									●							
NEW*: Biomotion Technologies FlexCo	●			●		●			●	●						●

	Active implantable devices	Anesthetic and respiratory devices	Assistive products for persons with disability	Biological-derived devices	Dental devices	Diagnostic and therapeutic radiation devices	Electromechanical medical devices	Hospital hardware	In-vitro diagnostic devices	Non-active implantable devices	Ophthalmic and optical devices	Reusable devices	Single-use devices	Software for medicine, telemedicine and e-health	Other products for healthcare	Additive manufacturing
Bloom Diagnostics GmbH									●					●		
Braincon GmbH & Co KG			●							●				●		
Brainhero GmbH							●							●		
BrightComSol GmbH						●										
NEW: Brightmind.AI GmbH														●		
NEW: CAATS Service GmbH														●		
Carl Reiner GmbH		●										●	●	●		
CogVis Software und Consulting GmbH							●								●	
CompuGroup Medical CEE GmbH														●		
Compumedics - alpha trace GmbH														●		
NEW*: Confideck GmbH														●		
contextflow GmbH														●		
Cubicure GmbH Align Technology																●
CVTec Cerebrovascular Technologies GmbH														●		
D.A.T.A. Corporation Software-entwicklungs GmbH														●		
Dedalus HealthCare Ges.m.b.H.								●						●		
Derma Medical Systems Handels- und Entwicklungs GmbH							●							●		
NEW: DEZIMAL GmbH											●					
Dr. Schuhfried Medizintechnik GmbH			●				●	●					●			
EMTensor GmbH							●									
Exomys-Augmented Humanity GmbH			●													●

	Active implantable devices	Anesthetic and respiratory devices	Assistive products for persons with disability	Biological-derived devices	Dental devices	Diagnostic and therapeutic radiation devices	Electromechanical medical devices	Hospital hardware	In-vitro diagnostic devices	Non-active implantable devices	Ophthalmic and optical devices	Reusable devices	Single-use devices	Software for medicine, telemedicine and e-health	Other products for healthcare	Additive manufacturing
F. Schmidl & Co GmbH			●													
FemPulse GmbH	●															
GETINGE Österreich GmbH												●				
HappyMed GmbH															●	
NEW: Health Force GmbH														●		
NEW: HearO GmbH														●		
heartfish GmbH														●		
hi.health GmbH														●		
IB Lab GmbH ImageBiopsy Lab														●		
NEW: Impairment Analytics DH2S GmbH														●		
Incus GmbH																●
Ing. Sumetzberger GmbH							●									
JEDER GmbH					●							●	●			
LeadMe HSW GmbH											●			●		
Lithoz GmbH																●
MacroArray Diagnostics GmbH MADx									●							
Mavie Next GmbH														●	●	
Medbee GmbH														●		
MedCom Medizinische Softwareerstellungs- und VertriebsgmbH														●		
Medexter Healthcare GmbH														●		
Medicus AI GmbH														●		
Medifina Medizinprodukte Vertriebs-GmbH														●		

	Active implantable devices	Anesthetic and respiratory devices	Assistive products for persons with disability	Biological-derived devices	Dental devices	Diagnostic and therapeutic radiation devices	Electromechanical medical devices	Hospital hardware	In-vitro diagnostic devices	Non-active implantable devices	Ophthalmic and optical devices	Reusable devices	Single-use devices	Software for medicine, telemedicine and e-health	Other products for healthcare	Additive manufacturing
MorphoMed GmbH				●						●					●	
NEW: myResQ GmbH														●		
mySugr GmbH Roche														●		
NEW: NanoVoxel GmbH	●	●						●	●	●	●	●	●			●
nyra health GmbH														●		
ONDEWO GmbH														●		
OrphaCare GmbH												●				
Orthorobot Medizintechnik GmbH					●											
Otto Bock Healthcare Products GmbH	●		●											●		
P+F Cardiovascular GmbH	●															
P+F Products + Features GmbH										●						
Pharma Consult Ges.m.b.H.															●	
Photonic Optische Geräte Gesellschaft m.b.H. & Co. KG								●								
piur imaging GmbH														●		
Plasmics GmbH			●									●			●	●
Platomics GmbH														●	●	
Pohlig Austria GmbH & Co KG										●						
NEW: psimistri GmbH														●		
REPULS Lichtmedizintechnik GmbH							●									
REPULS PDI GmbH						●										
RetInSight GmbH														●		
room4 Softwareentwicklung GmbH														●		

	Active implantable devices	Anesthetic and respiratory devices	Assistive products for persons with disability	Biological-derived devices	Dental devices	Diagnostic and therapeutic radiation devices	Electromechanical medical devices	Hospital hardware	In-vitro diagnostic devices	Non-active implantable devices	Ophthalmic and optical devices	Reusable devices	Single-use devices	Software for medicine, telemedicine and e-health	Other products for healthcare	Additive manufacturing
NEW: Roots Health GmbH Hello Inside														●		
rotatable technologies GmbH														●		
SCARLETRED Holding GmbH													●	●		
SIMCharacters GmbH Laerdal Medical														●	●	
SIMStation GmbH														●	●	
SNORE FREE GmbH														●		
Soma Reality GmbH Somareality														●	●	
NEW: speak23 GmbH														●		
Symptoma GmbH														●		
NEW: TETRAGON Braille Systems GmbH			●											●		
NEW*: TiliaHealth FlexCo														●		
Treetop Medical GmbH														●		
NEW*: Turn-Motion FlexCo			●													
TWO PI Signal Processing Applications GmbH														●	●	
UpNano GmbH																●
NEW: Valeriot FlexCo							●					●	●			
VISUAPPS GmbH														●		
Vitreabio GmbH											●					
VIVISOL Heimbehandlungsgeräte GmbH		●														
Wavesense Engineering GmbH											●					
NEW*: WaveVision GmbH														●	●	
Websinger GmbH												●	●			
XUND Solutions GmbH														●		

Table 17: Business focus of innovative medical device companies in Vienna




Figure 17: The focus of innovative medical device companies in Vienna at a glance
 (data: Table 17, multiple choice, the list is provided for general orientation regarding the thematic focus of the companies and does not constitute a binding regulatory classification or confirm the formal intended use of any products the companies develop or manufacture, LISAvienna makes no claim that the products in question are, in all cases, medical devices or in vitro diagnostics and accepts no liability for any such interpretations)

Focus of innovative biotechnology / pharmaceutical companies in Vienna

This list is not exhaustive. NEW: Founded in 2021, 2022 or 2023 NEW*: Founded in 2024	Agriculture, cosmetics, environment, nutrition, textiles, veterinary	Contract research, development, manufacturing and related screening or discovery services, materials, processes and software	Diagnostics and research reagents	Drug discovery and development	Manufacturing of in-house products	Other activities	Clinical research
a:head bio AG		●		●			
AbbVie GmbH							●
ABF Pharmaceutical Services GmbH GBA Group		●					
Ablevia biotech GmbH		●		●			
ab&cd innovations GmbH						●	
NEW: ADvantage Therapeutics GmbH				●			●
NEW: aitiologic GmbH		●	●				
Akribes Biomedical GmbH			●	●			●
NEW: Albius Sciences (Austria) GmbH				●			
Algonist Biotechnologies GmbH				●			
AlgOss Biotechnologies GmbH		●				●	
Alliance Medical BSM GmbH			●				
NEW*: All But Sugar GmbH Smiling Food	●						
NEW*: Alpine Biolabs FlexCo	●						
NEW: Altus Biolabs GmbH		●	●				
AMGEN GMBH							●
AnYxis Immuno-Oncology GmbH				●			
AOP Orphan Pharmaceuticals GmbH AOP Health				●			●
APEIRON Biologics AG Ligand Pharmaceuticals				●			
APEPTICO Forschung und Entwicklung GmbH				●			●

	Agriculture, cosmetics, environment, nutrition, textiles, veterinary	Contract research, development, manufacturing and related screening or discovery services, materials, processes and software	Diagnostics and research reagents	Drug discovery and development	Manufacturing of in-house products	Other activities	Clinical research
Aposcience AG			●				●
NEW*: ARIVA Med GmbH			●				
NEW: Aspire Innova GmbH			●				
Astellas Pharma Ges.m.b.H.							●
AstraZeneca Österreich GmbH							●
Attoquant Diagnostics GmbH		●					
NEW: Aurovir Pharma GmbH				●			
Austrianni GmbH				●			
Bayer Austria Gesellschaft .m.b.H							●
Bender MedSystems GmbH Thermo Fisher Scientific			●				
NEW: bespark bio GmbH		●					
NEW: BioCraft Pet Nutrition GmbH	●						
Biogen Austria GmbH							●
Biomay AG		●					
Biomedical International R+D GmbH	●			●		●	
Biomedizinische Forschung & Bio-Produkte GmbH				●			●
BioNTech R&D (Austria) GmbH				●			
Bioplant Research & Development GmbH	●						
Biosynth GmbH		●					
BIT BIO Discovery GmbH		●	●	●			
BlueSky Immunotherapies GmbH				●			●
Boehringer Ingelheim RCV GmbH & Co KG	●	●		●	●		●
Bristol-Myers Squibb GmbH							●

	Agriculture, cosmetics, environment, nutrition, textiles, veterinary	Contract research, development, manufacturing and related screening or discovery services, materials, processes and software	Diagnostics and research reagents	Drug discovery and development	Manufacturing of in-house products	Other activities	Clinical research
CALYXHA Biotechnologies GmbH				●			
NEW: CellEctric Biosciences GmbH		●	●				
ChanPharm GmbH		●					
Circe Biotechnologie GmbH	●						
NEW: CompreVie In Vitro Diagnostics GmbH	●	●					
Covirabio GmbH			●				
NEW: Cutanos GmbH		●		●			
Daiichi Sankyo Austria GmbH							●
NEW: dawn-bio GmbH				●			
Delta 4 GmbH		●		●			
DIPHA GmbH		●					
NEW*: Discovery Evolution FlexCo		●					
DONAUCHEM GmbH						●	
Eisai GesmbH							●
Eli Lilly Gesellschaft m.b.H.							●
NEW*: Elio Technologies FlexCo	●					●	
emergentec biodevelopment GmbH		●					
enGenes Biotech GmbH		●					
EQ-BOKU (Equipment-BOKU) - GmbH Connective Base GmbH		●					
Eurofins Genomics AT GmbH		●					
Europlasma GmbH						●	
EveliQure Biotechnologies GmbH				●			●
Evercyte GmbH			●				

	Agriculture, cosmetics, environment, nutrition, textiles, veterinary	Contract research, development, manufacturing and related screening or discovery services, materials, processes and software	Diagnostics and research reagents	Drug discovery and development	Manufacturing of in-house products	Other activities	Clinical research
NEW: Evobright GmbH				●			
Evologic Technologies GmbH	●	●					
NEW*: Exalt FlexCo			●				
F2G Biotech GmbH				●			
F4-Pharma Ges.m.b.H.				●			●
NEW*: Framami GmbH	●						
NEW*: Freundeskreis GmbH	●						
GC Genomics GmbH	●						
Germania Pharmazeutika GmbH					●		
Gilead Sciences GesmbH							●
GlaxoSmithKline Pharma GmbH							●
GLOBOPHARM Pharmazeutische Produktions- und Handelsgesellschaft mbH		●					
NEW*: Glycanostics GmbH			●				
G.ST Antivirals GmbH				●			●
HAPLOGEN Bioscience GmbH				●			
NEW: HD Immune GmbH				●			
NEW: HeartBeat.bio AG		●		●			
HG Pharma GmbH	●						
NEW: Holloid GmbH	●	●					
Hypericum LifeScience GmbH				●			
IDEPS GmbH	●						
NEW: imd BIOTECH GmbH	●		●				

	Agriculture, cosmetics, environment, nutrition, textiles, veterinary	Contract research, development, manufacturing and related screening or discovery services, materials, processes and software	Diagnostics and research reagents	Drug discovery and development	Manufacturing of in-house products	Other activities	Clinical research
ingenetix GmbH			●				
Intervet GesmbH MSD	●						
NEW: invIOs GmbH				●			●
IQVIA RDS GesmbH		●					
Janssen-Cilag Pharma GmbH							●
JLP Health GmbH				●			
Jungbunzlauer Austria AG	●						
Kiora Pharmaceuticals GmbH				●			●
NEW: Körber Pharma Austria GmbH		●					
Kwizda Agro GmbH	●						
Kwizda Pharma GmbH	●	●		●	●		●
LABDIA Labordiagnostik GmbH			●				
NEW: lablife gmbh						●	
LEICA Mikrosysteme, Beckman Coulter Life Sciences, Cytiva Danaher						●	
Lexogen GmbH			●				
LIVIN farms AgriFood GmbH	●						
NEW: LoopLab Bio GmbH				●			
NEW: Luna-IP GmbH						●	
Lundbeck Austria GmbH							●
NEW: MAG-LAB GmbH		●					
NEW: Magmatic Bio GmbH	●						
Mark53 GmbH			●				

	Agriculture, cosmetics, environment, nutrition, textiles, veterinary	Contract research, development, manufacturing and related screening or discovery services, materials, processes and software	Diagnostics and research reagents	Drug discovery and development	Manufacturing of in-house products	Other activities	Clinical research
Marwian GmbH						●	
Merck Chemicals and Life Science GesmbH							●
Merck Sharp & Dohme GmbH							●
NEW*: MetabolizeMe GmbH	●		●				
Microsynth Austria GmbH		●					
Miti Biosystems GmbH		●					
MoNo chem-pharm Produkte GmbH		●					
Myelopro Diagnostics and Research GmbH				●			
Myllia Biotechnology GmbH		●		●			
NEW: MyPilz GmbH	●	●					
NEW: nagene GmbH		●					
NBS-C BioScience & Consulting GmbH		●					
NEW: NDx Bio GmbH	●		●				
NEW: New Path Bio GmbH	●						
Novartis Pharma GmbH							●
Novasign GmbH		●					
NEW: NovoArc GmbH		●			●		
Novo Nordisk Pharma GmbH							●
Nuvonis Technologies GmbH		●					
Octapharma Pharmazeutika Produktionsgesellschaft mbH				●	●		●
NEW: OFS Lipid Legends GmbH	●						
NEW: OMV Green Energy GmbH	●						
NEW*: PathoCap GmbH				●			

	Agriculture, cosmetics, environment, nutrition, textiles, veterinary	Contract research, development, manufacturing and related screening or discovery services, materials, processes and software	Diagnostics and research reagents	Drug discovery and development	Manufacturing of in-house products	Other activities	Clinical research
PEZZ life GmbH	●						
Pfizer Corporation Austria GmbH							●
Pivaris BioScience GmbH				●			
PLANTA Naturstoffe Vertriebsges.m.b.H.							
ProFem GmbH				●			●
NEW: Proglycan GmbH			●				
Proxygen GmbH				●			
NEW: QC3 GmbH		●					
QUANTRO Therapeutics GmbH		●		●			
NEW: QUBICON AG		●					
NEW: Regenera GmbH				●			
NEW: Revo Foods GmbH	●						
NEW: RIANA Therapeutics GmbH				●			
Ribbon Biolabs GmbH		●	●				
Roche Austria GmbH							●
NEW: Rockfish Bio AG				●			
NEW: Rosta Biotech GmbH		●					
SAICO Biosystems KG		●					
SANOFI-AVENTIS GmbH							●
Schwabe Austria GmbH				●	●		●
Sigmapharm Arzneimittel GmbH		●					
S-TARget therapeutics GmbH				●			
NEW*: Supercoiled GeneTx GmbH		●					

	Agriculture, cosmetics, environment, nutrition, textiles, veterinary	Contract research, development, manufacturing and related screening or discovery services, materials, processes and software	Diagnostics and research reagents	Drug discovery and development	Manufacturing of in-house products	Other activities	Clinical research
Syconium Lactic Acid GmbH	●						
Takeda Manufacturing Austria AG				●	●		●
TAmiRNA GmbH		●	●				
Technoclone Herstellung von Diagnostika und Arzneimitteln Gesellschaft m.b.H.		●	●		●		
The Antibody Lab GmbH		●					
Thoeris GmbH				●			
THT BIOMATERIALS GmbH		●					
TissueGnostics GmbH			●				
Tridem Bioscience GmbH & Co KG				●			
Trigal Pharma GmbH							●
UCB Pharma Gesellschaft m.b.H.							●
usePAT GmbH	●	●					
Valneva Austria GmbH				●			●
VelaLabs GmbH Tentamus Group		●					
NEW: VERDI Solutions GmbH		●		●			●
VIDIPHARM GmbH			●				
Vienna Biocenter Core Facilities GmbH		●					
ViennaLab Diagnostics GmbH Biovendor Group			●				
Virusure Forschung und Entwicklung GmbH Asahi Kasei Medical Group	●	●					
Vita 34 Gesellschaft für Zelltransplantate m.b.H. FamiCord		●					
Vivaldi Biosciences AG				●			●

	Agriculture, cosmetics, environment, nutrition, textiles, veterinary	Contract research, development, manufacturing and related screening or discovery services, materials, processes and software	Diagnostics and research reagents	Drug discovery and development	Manufacturing of in-house products	Other activities	Clinical research
NEW*: ViVerita Discovery FlexCo		●		●			
VOGELBUSCH Biocommodities GmbH	●	●					
VOGELBUSCH Biopharma GmbH		●					
NEW: VTL GmbH Vienna Textile Lab	●						
YASARA Biosciences GmbH		●					
NEW: YGION Biomedical GmbH				●			
Zytoprotec Flexible Kapitalgesellschaft				●			●

Table 18: Business focus of innovative biotechnology / pharmaceutical companies in Vienna




Figure 18: The focus of innovative biotechnology / pharmaceutical companies in Vienna at a glance (data: Table 18, multiple choice)

Drug discovery and development in Vienna

This list is not exhaustive. NEW: Founded in 2021, 2022 or 2023 NEW*: Founded in 2024																			
	Blood and the immune system	Circulatory system	Digestive system	Endocrine and metabolic diseases	Eye and the ear	Genitourinary system	Infectious diseases	Neoplasms	Nervous system	Respiratory system	Skin and subcutaneous tissue	Other indications							
a:head bio AG								●											
Ablevia biotech GmbH	●											●							
NEW: ADvantage Therapeutics GmbH								●											
Akribes Biomedical GmbH											●								
NEW: Albius Sciences (Austria) GmbH							●	●		●		●							
Algonist Biotechnologies GmbH									●										
AnYxis Immuno-Oncology GmbH	●							●											
AOP Orphan Pharmaceuticals GmbH AOP Health	●	●						●	●	●									
APEIRON Biologics AG Ligand Pharmaceuticals	●							●											
APEPTICO Forschung und Entwicklung GmbH										●									
Aposcience AG		●		●							●								
NEW*: ARIVA Med GmbH							●												
NEW: Aspire Innova GmbH							●											●	
NEW: Aurovir Pharma GmbH										●									
Austrianni GmbH							●												
Biomedical International R+D GmbH	●																		
Biomedizinische Forschung & Bio-Produkte GmbH	●						●												
BioNTech R&D (Austria) GmbH							●			●									
BIT BIO Discovery GmbH	●			●					●									●	
BlueSky Immunotherapies GmbH	●						●	●											
Boehringer Ingelheim RCV GmbH & Co KG								●											
CALYXHA Biotechnologies GmbH	●									●									
NEW: Cutanos GmbH	●						●				●								
NEW: dawn-bio GmbH						●													

	Blood and the immune system	Circulatory system	Digestive system	Endocrine and metabolic diseases	Eye and the ear	Genitourinary system	Infectious diseases	Neoplasms	Nervous system	Respiratory system	Skin and subcutaneous tissue	Other indications
Delta 4 GmbH		●		●		●						
EveliQure Biotechnologies GmbH			●				●					
NEW: Evobright GmbH	●							●				
F2G Biotech GmbH							●					
F4-Pharma Ges.m.b.H.	●	●					●			●		●
G.ST Antivirals GmbH							●			●		
HAPLOGEN Bioscience GmbH			●	●								
NEW: HD Immune GmbH									●			
NEW: HeartBeat.bio AG		●										
Hypericum LifeScience GmbH								●				
NEW: invIOs GmbH								●				
JLP Health GmbH							●	●				
Kiora Pharmaceuticals GmbH					●							
Kwizda Pharma GmbH		●		●		●						
NEW: LoopLab Bio GmbH	●		●								●	
Myelopro Diagnostics and Research GmbH	●							●				
Myllia Biotechnology GmbH	●							●				●
Octapharma Pharmazeutika Produktionsgesellschaft mbH	●									●		
NEW*: PathoCap GmbH							●					
Pivaris BioScience GmbH							●					
ProFem GmbH						●						
Proxygen GmbH	●		●	●		●	●	●	●	●		
QUANTRO Therapeutics GmbH								●				
NEW: Regenera GmbH									●			
NEW: RIANA Therapeutics GmbH								●				
NEW: Rockfish Bio AG	●	●	●			●			●	●	●	●

	Blood and the immune system	Circulatory system	Digestive system	Endocrine and metabolic diseases	Eye and the ear	Genitourinary system	Infectious diseases	Neoplasms	Nervous system	Respiratory system	Skin and subcutaneous tissue	Other indications
Schwabe Austria GmbH			●						●	●		
S-TARget therapeutics GmbH	●											
Takeda Manufacturing Austria AG	●											
Thoeris GmbH						●						
Tridem Bioscience GmbH & Co KG									●			
Valneva Austria GmbH							●					
NEW: VERDI Solutions GmbH								●				
Vivaldi Biosciences AG							●					
NEW*: ViVerita Discovery FlexCo								●				
NEW: YGION Biomedical GmbH								●				
Zytoprotec Flexible Kapitalgesellschaft												●

Table 19: Drug discovery and development in Vienna




Figure 19: Drug discovery and development in Vienna at a glance (data: Table 19, multiple choice)

Imprint

Publisher

ARGE LISAvienna | Karl-Farkas-Gasse 18 | 1030 Vienna, Austria

Editors

WPZ Research GmbH | Mariahilferstrasse 115/16 | 1060 Vienna, Austria:
Sascha Sardadvar, Brigitte Ecker

ARGE LISAvienna | Karl-Farkas-Gasse 18 | 1030 Vienna,
Austria: Brigitte Tempelmaier, Philipp Hainzl

Layout

WPZ Research GmbH | Mariahilferstrasse 115/16 | 1060 Vienna, Austria:
Ricarda Ecker

The free use of all contents is expressly permitted.

Citation suggestion short: Vienna Life Science Report 2024/25

Citation suggestion long: S. Sardadvar, B. Tempelmaier, Ph. Hainzl, B. Ecker
(2025): Vienna Life Science Report 2024/25

A PDF edition is available at www.LISAvienna.at.

